REPORT OF THE 387th CELL EXCHANGE
JUNE 3, 2015

B-cell Lines	**515-516**
Cells	**1545-1548**
Serum	**1173-1176**

B-cell Line Exchange #258

The results for B-cell Line Exchange #258 are summarized in Tables 1 - 2 and individual laboratory results reported for each sample are listed in Tables 3 - 8. We are most grateful to **Helen Bass, Jane Rowlands, and Tracy Rees, Welsh Blood Service, Pontyclun** and to **Franz Claas, Leiden University Medical Centre, Leiden**, for providing us with the interesting cells typed in our studies. The haplotype frequencies used in this report are from the NMDP Bioinformatics website, http://bioinformatics.nmdp.org/.

Ter-515. The consensus type for this sample is DRB1*07:01-DRB1*13:36-DRB3*03:01-DRB4*01:01-DQA1*01:02-DQA1*02:01-DQB1*02:02-DQB1*06:09-DPA1*01:03-DPB1*02:01-DPB1*04:01-A*23:01-A*32:01-B*41:02-B*44:03-C*04:01-C*17:03. One possible association present in this cell may be A*32:01-B*41:02-DRB1*13:36-DRB3*03:01-DQA1*01:02-DQB1*06:09-DPB1*04:01, observed in RD-DJ, one of the reference cells for DRB1*13:36. The other likely association is A*23:01-B*44:03-DRB1*07:01-DRB4*01:01-DQA1*02:01-DQB1*02:02-DPB1*02:01.

This sample is 30638, a reference cell for DRB1*13:36. It was previously studied as Ter 446 (2010), Ter 360 (2005), and Ter 319 (2003), as astutely noted by Rao and Tiercy. In this retyping, DRB1*13:36 was assigned by 97% of labs reporting at high resolution. DRB1*07:01 (100%) was reported as the second DRB1 type, with 4 labs assigning DRB1*07:01:01. DQB1*02:02 (97%) and DQB1*06:09 (100%) were well typed as the DQB1 types. DQB1*02:02:01 and DQB1*06:09 were each assigned by 4 labs. The assignments of DPB1*01:02 and DPB1*04:01 improved, increasing from a detection level of 83% and 79%, respectively, in 2010, to 97% and 100% in this present typing.

The class I types for this sample were reported as A*23:01 (100%), A*32:01 (100%), B*41:02 (100%), B*44:03 (100%), C*04:01 (95%), and C*17:03 (68%).

Ter-516. The consensus type for this sample from an Asian donor is DRB1*13:13-DRB1*15:02-DRB5*01:01-DQA1*01:02-DQA1*05:05-DQB1*03:01-DQB1*05:02-DPA1*02:02-DPB1*01:01-DPB1*05:01/*135:01-A*11:01-A*24:02-B*27:06-B*48:01-C*01:02-C*08:01. One possible association in this cell may be A*24:02-B*48:01-DRB1*15:02-DQB1*05:02, with HF=0.00089, in Asians. The other likely association present is A*11:01-B*27:06-DRB1*13:13-DQB1*03:01.

This sample was previously studied as Ter 433 (2009) and Ter 269 (2000), as correctly identified by Kvam, Rao, and Tiercy. It is the reference cell for DRB1*13:13, known as XX406 (1). In this present retyping, DRB1*13:13 and DRB1*15:02 were each assigned in complete consensus. Arnold, Costeas, Hahn, Pancoska, Rao, and Tiercy commented on the absence of DRB3, despite the presence of DRB1*13:13. Interestingly, 2 out of 3 serology labs did report DR52. Anholts et al, describes the DRB*13:13-DRB3-negative association in this cell as likely representing “a recombination between a DR8 and DR13 haplotype. The HV2-HV3 region, together with the telomeric DRB1*0803 class II region, of course lacking DRB3, possibly recombined with the HV1 of DRB1*1303 and the centromeric part of that haplotype, including DQA1*0501, DQA1*0301” (1). DRB5*01:01 was reported by 100%. DPB1*01:01 (100%) was well assigned. The assignment of the second DPB1 type, however, remained unresolved, as 15 labs reported DPB1*135:01, 5 reported DPB1*05:01, 4 reported DPB1*05:01:01G, 5 reported DPB1*05:01/*135:01, 1 reported DPB1*05:01P, and 1 reported DPB1*05:01/*135:01/*+. DPB1*135:01 “was found identical to DPB1*05:01 in exon 2 sequence, but showed a non-synonymous substitution in exon 4 and a nucleotide deletion in exon 5” (2).

This sample was also typed for class I as extracts 250 (2003) and 165 (2001). In this present retyping, the class I types were well assigned as A*11:01 (100%), A*24:02 (100%), B*27:06 (100%), B*48:01 (100%), C*01:02 (95%), C*08:01 (95%).

References:

1. Anholts JDH, Verduijn W, Drabbels J, et al. Identification of two new alleles HLA-DRB1*0312, DRB1*0432 and of a DRB3-negative DRB1*1313-positive haplotype. Tissue Antigens 2000;56:87-89.
2. Lauterbach N, Voorter CEM, Stallinga CMHA, et al. Full-length HLA-DPB1 diversity in multiple alleles of individuals from Caucasian, Black, or Oriental origin. Tissue Antigens 2012;79:165-173.

Table 1: Summary of the 258th B-cell Line Exchange

Ter-515

DNA Typing - class II

35 labs High; 37 labs low-DRB1	%(n)
DRB1*07:01:01:01	3 (1)
DRB1*07:01:01	9 (3)
DRB1*07:01:01G	3 (1)
DRB1*07:01	85(30)
DRB1*07	100(37)

24 labs High; 27 labs Low-DRB3	%(n)
DRB3*03:01	96(23)
*DRB3*01:01*	4 (1)
DRB3*03	59(16)
*DRB3*01*	11(3)
DRB3*PRESENT	30(8)

22 labs High; 22 labs Low-DQA1	%(n)
DQA1*01:02:01	5 (1)
DQA1*01:02:01G	9 (2)
DQA1*01:02	86(19)
DQA1*01	100(22)

33 labs High; 35 labs Low-DQB1	%(n)
DQB1*02:02:01	12(4)
DQB1*02:02	85(28)
*DQB1*02:06*	3 (1)
DQB1*02	100(35)

15 labs High; 13 labs Low-DPA1	%(n)
DPA1*01:03:01	7 (1)
DPA1*01:03	93(14)
DPA1*01	92(12)
*DPA1*02*	8 (1)

30 labs High; 14 labs Low-DPB1	%(n)
DPB1*02:01:02	10(3)
DPB1*02:01:02G	7 (2)
DPB1*02:01	80(24)
*DPB1*141:01*	3 (1)
DPB1*02	93(13)
*DPB1*01*	7 (1)

36 labs High; 37 labs low-DRB1	%(n)
DRB1*13:36	97(35)
*DRB1*13:135*	3 (1)
DRB1*13	100(37)

20 labs High; 28 labs Low-DRB4	%(n)
DRB4*01:01:01:01	5 (1)
DRB4*01:01	95(19)
DRB4*01	68(19)
DRB4*PRESENT	32(9)

24 labs High; 20 labs Low-DQA1	%(n)
DQA1*02:01	100(24)
DQA1*02	100(20)

33 labs High; 35 labs Low-DQB1	%(n)
DQB1*06:09:01	12(4)
DQB1*06:09	88(29)
DQB1*06	100(35)

30 labs High; 14 labs Low-DPB1	%(n)
DPB1*04:01:01:01	3 (1)
DPB1*04:01:01	3 (1)
DPB1*04:01:01G	7 (2)
DPB1*04:01	87(26)
DPB1*04(DP0401)	36(5)
DPB1*04	57(8)
*DPB1*05*	7 (1)

Serology - class II

3 LABS - DR	%(n)
DR7	100(3)
DR13	100(3)

DR52	100(3)
DR53	67(2)

3 LABS - DQ	%(n)
DQ2	100(3)
DQ1	100(3)

DNA Typing - class I

19 labs High; 26 labs low- A	%(n)
A*23:01:01	11(2)
A*23:01:01G	5 (1)
A*23:01P	5 (1)
A*23:01	79(15)
A*23	100(26)

21 labs High; 25 labs low- B	%(n)
B*41:02:01	19(4)
B*41:02	81(17)
B*41	100(25)

19 labs High; 26 labs low- C	%(n)
C*04:01:01:01	5 (1)
C*04:01:01	5 (1)
C*04:01P	11(2)
C*04:01	74(14)
*C*04:09N*	5 (1)
C*04	100(26)

19 labs High; 26 labs low- A	%(n)
A*32:01:01	11(2)
A*32:01	89(17)
A*32	100(26)

21 labs High; 25 labs low- B	%(n)
B*44:03:01	14(3)
B*44:03:02	5 (1)
B*44:03	81(17)
B*44	100(25)

19 labs High/Inter; 26 labs low- C	%(n)
C*17:01:01G	5 (1)
C*17:03	68(13)
*C*17:01*	11(2)
C*17:01+	16(3)
C*17	100(26)

Table 2: Summary of the 258th B-cell Line Exchange

Ter-516

DNA Typing - class II

36 labs High; 37 labs low-DRB1	%(n)
DRB1*13:13	100(36)
DRB1*13	94(35)
*DRB1*08*	3 (1)
*DRB1*14*	3 (1)

23 labs High; 25 labs Low-DRB5	%(n)
DRB5*01:01:01	4 (1)
DRB5*01:01	96(22)
DRB5*01	72(18)
DRB5*PRESENT	28(7)

21 labs High; 22 labs Low-DQA1	%(n)
DQA1*01:02:01	5 (1)
DQA1*01:02:01G	10(2)
DQA1*01:02	85(18)
DQA1*01	100(22)

34 labs High; 35 labs Low-DQB1	%(n)
DQB1*03:01:01:01	3 (1)
DQB1*03:01:01	6 (2)
DQB1*03:01:01G	3 (1)
DQB1*03:01	88(30)
DQB1*03(DQ7)	6 (2)
DQB1*03	94(33)

15 labs High; 13 labs Low-DPA1	%(n)
DPA1*02:02:02	7 (1)
DPA1*02:02	86(13)
*DPA1*02:01*	7 (1)
DPA1*02	92(12)
*DPA1*01*	8 (1)

29 labs High; 15 labs Low-DPB1	%(n)
DPB1*01:01:01	7 (2)
DPB1*01:01:01G	3 (1)
DPB1*01:01:02G	3 (1)
DPB1*01:01	86(25)
DPB1*01	93(14)
*DPB1*02*	7 (1)

35 labs High; 38 labs low-DRB1	%(n)
DRB1*15:02:01	14(5)
DRB1*15:02	86(30)
DRB1*15	100(38)

21 labs High; 21 labs Low-DQA1	%(n)
DQA1*05:05:01	5 (1)
DQA1*05:01:01G	5 (1)
DQA1*05:05	90(19)
DQA1*05	95(20)
*DQA1*03*	5 (1)

32 labs High; 35 labs Low-DQB1	%(n)
DQB1*05:02:01	13(4)
DQB1*05:02	84(27)
*DQB1*05:05*	3 (1)
DQB1*05	100(35)

30 labs High/Int; 9 labs Low-DPB1	%(n)
DPB1*05:01:01G	13(4)
DPB1*05:01P	3 (1)
DPB1*135:01	50(15)
DPB1*05:01	17(5)
DPB1*05:01/*135:01	13(4)
DPB1*05:01/*135:01/*+	3 (1)
DPB1*05	89(8)
*DPB1*04*	11(1)

Serology - class II

3 LABS- DR	%(n)
DR13	100(3)
DR15	100(3)

DR51	100(3)
DR52	67(3)

3 LABS - DQ	%(n)
DQ1	100(3)
DQ7	100(3)

DNA Typing - class I

19 labs High; 26 labs low- A	%(n)
A*11:01:01	11(2)
A*11:01	84(16)
*A*11:12*	5 (1)
A*11	100(26)

20 labs High; 25 labs low- B	%(n)
B*27:06	100(20)
B*27	100(25)

19 labs High; 26 labs low- C	%(n)
C*01:02:01	11(2)
C*01:02:01G	11(2)
C*01:02	73(14)
*C*04:01*	5 (1)
C*01	100(26)

19 labs High; 26 labs low- A	%(n)
A*24:02:01:01	5 (1)
A*24:02:01G	5 (1)
A*24:02	90(17)
A*24	100(26)

20 labs High; 25 labs low- B	%(n)
B*48:01:01	20(4)
B*48:01	80(16)
B*48	100(25)

19 labs High; 26 labs low- C	%(n)
C*08:01:01	11(2)
C*08:01:01G	11(2)
C*08:01	73(14)
*C*17:01*	5 (1)
C*08	100(26)

Table 3a: Individual laboratory results for B-cell #515-Class II

		Low resolution												
Center	**Investigator**	**DRB1**		**DRB3**	**DRB4**	**DQA1**		**DQB1**		**DPA1**		**DPB1**		**METHOD**
5488	Adams , Sharon				4*01	*01				NT				SSP SSO SBT
4691	Al Ajlan , Abdulaziz							*02	*06					SSO
8070	Chang , Uckjin	*07	*13											SSP
9916	Charlton , Ronald K	*07	*13	3*PRESENT	4*PRESENT			*02	*06					SSP SBT
3224	Chen , Dong-Feng	*07	*13	3*01	4*01	*01	*02	*02	*06	*01		*02	*04	SSP SSO SBT
8021	Clark , Brendan			3*03	4*01	*01	*02	*02	*06					SSP SSO
3632	Colombe , Beth W.	*07	*13	3*03	4*01	*01	*02	*02	*06	*01		*02	*04	SSP SSO
779	Daniel , Claude	*07	*13	3*03	4*01	*01	*02	*02	*06	*01		*02	*04(DP0401)	SSP SSO
5219	Daniel , Dolly	*07	*13					*02	*06					
1108	DeConinck , Martha	*07	*13	3*03	4*01	*01	*02	*02	*06	*01				
3766	Dunn , Paul	*07	*13	3*03	4*01	*01		*02	*06					
5214	Eckels/CPMC ,	*07	*13	3*03	4*01	*01	*02	*02	*06	*01		*02	*04(DP0401)	
4079	Fort , Marylise	*07	*13					*02	*06					SSP
792	Gandhi , Manish	*07	*13	3*03	4*01	*01	*02	*02	*06	*01	*01	*02	*04	
8087	Guerra , Q.F.B. Elb	*07	*13					*02	*06					SSO
910	Hahn , Amy B.	*07	*13	3*PRESENT	4*PRESENT			*02	*06					SSP
1694	Hesse , Nicole	*07	*13	3*PRESENT	4*PRESENT			*02	*06					SSP
8043	Hod , Reut	*07	*13					*02	*06					
771	Israel , Shoshana	*07	*13					*02	*06					SSP SSO
794	Jaatinen , Taina	*07	*13											SSP SSO SBT
2847	Kihara , Masaaki	*07	*13											SSO
87	Land , Geoffrey A.	*07	*13	3*03	4*01	*01	*02	*02	*06	*01	*01	*02	*04	SSP SSO SBT
725	Lardy , N.M.	*07	*13	3*PRESENT	4*PRESENT	*01	*02	*02	*06					SSP SSO
278	Lee , Jar-How	*07	*13	3*03	4*01	*01	*02	*02	*06	*01		*02	*04	SSP SSO
6649	Lim , Young Ae	*07	*13	3*PRESENT	4*PRESENT									SSP
759	Lopez-Cepero , Ma	*07	*13	3*03	4*01	*01	*02	*02	*06	*01		*02	*04(DP0401)	SSP
206	McAlack-Hanau ,	*07	*13	3*03	4*01	*01	*02	*02	*06	*02		*01	*05	
8042	Muncher , Liora	*07	*13	3*03	4*01	NT	NT	*02	*06	NT	NT	NT	NT	SSP SBT
54	Pancoska , Carol	*07	*13	3*01	4*01	*01	*02	*02	*06	*01		*02	*04	SSO
2400	Phelan , Donna L.	*07	*13	3*03	4*01	*01	*02	*02	*06			*02	*04	SSP SSO SBT
8001	Rao , Prakash					*01	*02							SSP SSO
3519	Renac , Virginie	*07	*13					*02	*06			*02	*04(DP0401)	SSP SBT
1160	Rosen-Bronson , S	*07	*13	3*03	4*01	*01	*02	*02	*06	*01		*02	*04	SSO SBT
793	Rubocki , Ronald	*07	*13	3*03	4*PRESENT	*01	*02	*02	*06					SSP
4251	Schiller , Jennifer	*07	*13	3*03	4*01	*01	*02	*02	*06	*01	*01	*02	*04(DP0401)	SSO SBT
8068	Shanmugam , Hem	*07	*13	3*PRESENT	4*PRESENT			*02	*06					SSP
8029	Tarigopula , Anil	*07	*13					*02	*06					SSO
747	Tiercy , Jean-Marie	*07	*13	3*PRESENT	4*PRESENT	*01	*02	*02	*06					SSP SSO SBT
5451	Tilanus , Marcel G.	*07	*13	3*PRESENT	4*PRESENT			*02	*06					SSP SBT
5642	Varnavidou-Nicolai	*07	*13	3*01	4*01			*02	*06					
8052	Yanina Marcos , Ci	*07	*13			*01	*02	*02	*06					SSO

Table 3b: Individual laboratory results for B-cell #515-Class II											
	Serology										
CTR	DIRNAME	DR7	DR13	DR52	DR53			DQ2	DQ1	OTH1	OTH2
4492	Charron,D.	+	+	+	+			+	+		
910	Hahn,Amy B.	+	+	+	+			+	+		
4908	Kvam,Vonnett	+	+	+				+	+		

Table 4: Individual laboratory results for B-cell #515-Class II														
		High resolution												
Center	Investigator	DRB1		DRB3	DRB4	DQA1		DQB1		DPA1	DPB1		METHOD	Other Alleles
5488	Adams , Sharon	*07:01:01	*13:36	3*03:01			*02:01	*02:02:01	*06:09:01		*02:01:02	*04:01:01	SSP SSO SBT	DQA1*01:02/01:08/01:09/01:11
4691	Al Ajlan , Abdulaziz	*07:01	*13:36										SSO	
5462	Arnold , Paula	*07:01	*13:36	3*03:01	4*01:01	NT	NT	*02:02	*06:09	NT	*02:01	*04:01	SSP SSO SBT	DQB1*02:12
774	Cecka , J. Michael	*07:01	*13:36	3*03:01	4*01:01	*01:02	*02:01	*02:02	*06:09	*01:03	*02:01	*04:01	SSP SSO	DRB1*07:18/07:19/07:21/07:23/07:24/07:25/07:27/07:28/07:29/07:30/07:31/07:32/07:33/07:34, DQB1*02:06/02:10/02:11/02:12, DQB1*06:88/06:121/06:142
9916	Charlton , Ronald K	*07:01:01	*13:36	3*03:01	4*01:01:01:01			*02:02:01	*06:09:01				SSP SBT	
4492	Charron , Dominiqu	*07:01	*13:36	3*03:01	4*01:01	*01:02	*02:01	*02:02	*06:09	*01:03	*02:01	*04:01	SSP SSO	DRB1*07:31/07:33/07:34, DQB1*02:12, DQB1*06:88, DQA1*01:08/01:09/01:11, DPB1*217:01/218:01N/237:01/239:01/258:01/261:01/273:01/359:01/216:01N/224:01/225:01/228:01/230:01/231:01/232:01/240:01/253:01/262:01
3224	Chen , Dong-Feng	*07:01	*13:36	3*01:01	4*01:01	*01:02:01G	*02:01	*02:02	*06:09	*01:03	*02:01:02	*04:01	SSP SSO SBT	
8021	Clark , Brendan	*07:01	*13:36	3*03:01		*01:02	*02:01	*02:02	*06:09		*02:01	*04:01	SSP SSO	DRB1*07:25/07:26N/07:27/07:28, DQA1*01:08/01:09/01:11, DQB1*02:12, DQB1*06:88
3632	Colombe , Beth W.	*07:01	*13:36	3*03:01	4*01:01	*01:02	*02:01	*02:02	*06:09	*01:03	*02:01	*04:01	SSP SSO	
5130	Costeas , Paul A.	*07:01	*13:36	3*03:01	4*01:01	*01:02	*02:01	*02:02	*06:09					
779	Daniel , Claude		*13:36	3*03:01		*01:02	*02:01			*01:03	*02:01	*04:01	SSP SSO	
3766	Dunn , Paul						*02:01			*01:03	*02:01	*04:01		
3135	Enczmann , J	*07:01	*13:36	3*03:01	4*01:01			*02:02	*06:09		*02:01	*04:01		
762	Fischer , Gottfried	*07:01	*13:36	3*03:01	4*01:01	*01:02	*02:01	*02:02	*06:09		*02:01	*04:01	SSP SSO SBT	DRB1*07:23, DRB4*01:06
4079	Fort , Marylise										*02:01	*04:01	SSP	DRB1*334:01
792	Gandhi , Manish	*07:01	*13:36			*01:02	*02:01	*02:02	*06:09		*02:01	*04:01		
810	Hamdi , Nuha	*07:01	*13:36	3*03:01	4*01:01	*01:02	*02:01	*02:02	*06:09				SSO	DRB1*07:31, DRB4*01:03/01:06, DQA1*01:08/01:09, DQB1*02:12, DQB1*06:88
8043	Hod , Reut	*07:01	*13:36			*01:02	*02:01	*02:02	*06:09	*01:03	*02:01	*04:01		

Table 4: Individual laboratory results for B-cell #515-Class II														
		High resolution												
Center	Investigator	DRB1		DRB3	DRB4	DQA1		DQB1		DPA1	DPB1		METHOD	Other Alleles
2344	Hurley , Hartzman&	*07:01:01:01	*13:36			*01:02:01	*02:01	*02:02:01	*06:09:01	*01:03:01	*02:01:02	*04:01:01:01	OTHER	DRB1*07:01:01:02, DPB1*04:01:01:02
771	Israel , Shoshana	*07:01	*13:36					*02:02	*06:09				SSP SSO	
794	Jaatinen , Taina	*07:01	*13:36	3*03:01	4*01:01	*01:02	*02:01	*02:02	*06:09	*01:03	*02:01	*04:01	SSP SSO SBT	DQA1*01:08/01:09/01:11
8086	Jie , Pan	*07:01	*13:36			*01:02	*02:01	*02:02	*06:09	*01:03	*02:01	*04:01	SBT	
4337	Kim , Tai-Gyu	*07:01	*13:36					*02:02	*06:09		*02:01	*04:01	SBT	
87	Land , Geoffrey A.	*07:01	*13:36	3*03:01	4*01:01	*01:02	*02:01	*02:02	*06:09	*01:03	*02:01	*04:01	SSP SSO SBT	
278	Lee , Jar-How	*07:01	*13:36	3*03:01	4*01:01	*01:02	*02:01	*02:02	*06:09	*01:03	*02:01	*04:01	SSP SSO	
274	Lo , Raymundo W.	*07:01	*13:135			*01:02	*02:01	*02:02	*06:09	*01:03	*141:01	*04:01		
8042	Muncher , Liora	*07:01	*13:36	3*03:01	4*01:01	NT	NT	*02:02	*06:09	NT	NT	NT	SSP SBT	
54	Pancoska , Carol												SSO	
3966	Permpikul , Vejbaes	*07:01	*13:36	3*03:01	4*01:01			*02:02	*06:09				SSP	
2400	Phelan , Donna L.	*07:01	*13:36			*01:02	*02:01	*02:02	*06:09		*02:01:02G	*04:01:01G	SSP SSO SBT	
8001	Rao , Prakash	*07:01	*13:36	3*03:01	4*01:01			*02:02	*06:09		*02:01	*04:01	SSP SSO	
3753	Reed , Elaine F.	*07:01	*13:36	3*03:01	4*01:01	*01:02:01G	*02:01	*02:02	*06:09	*01:03	*02:01	*04:01	SSP SSO SBT	DQB1*02:01, DQB1*06:05, DRB4*01:03/01:06/01:08, DPB1*23:01/33:01/51:01/71 :01/81:01/105:02
3519	Renac , Virginie	*07:01	*13:36	3*03:01	4*01:01	*01:02	*02:01	*02:02	*06:09		*02:01	*04:01	SSP SBT	DRB1*07:34
1160	Rosen-Bronson , Sa	*07:01	*13:36	3*03:01				*02:02	*06:09	*01:03	*02:01	*04:01	SSO SBT	DRB1*07:26N, DQB1*02:12, DQB1*06:88
793	Rubocki , Ronald										*02:01	*04:01	SSP	
4251	Schiller , Jennifer	*07:01:01G	*13:36					*02:02	*06:09		*02:01:02G	*04:01:01G	SSO SBT	
747	Tiercy , Jean-Marie	*07:01	*13:36	3*03:01	4*01:01	*01:02	*02:01	*02:02:01	*06:09:01		*02:01	*04:01	SSP SSO SBT	DQA1*01:08/01:09/01:11
5451	Tilanus , Marcel G.J	*07:01:01	*13:36										SSP SBT	
5642	Varnavidou-Nicolaid	*07:01	*13:36					*02:06	*06:09					
3511	Zeevi , Adriana	*07:01	*13:36	3*03:01	4*01:01	*01:02	*02:01	*02:02	*06:09		*02:01	*04:01	SSP SSO	

Table 5: Individual laboratory results for B-cell #515-Class I															
		Low Resolution						High/Intermediate resolution							
Center	Investigator	HLA-A		HLA-B		HLA-C		HLA-A		HLA-B		HLA-C		METHOD	Other Alleles
5488	Adams , Sharon	*23	*32			*04	*17			*41:02:01	*44:03:01			SSP SSO SBT	A*23:01:01/23:03:01/23:04/23:17/23:36, A*32:01:01/32:03/32:13/32:28, C*04:01/04:09N/04:30/04:32/04:82, C*17:02/17:01/17:03/17:23
4691	Al Ajlan , Abdulaziz	*23	*32	*41	*44	*04	*17							SSO	
5462	Arnold , Paula							*23:01P	*32:01	*41:02	*44:03	*04:01P	*17:03	SSP SSO SBT	
774	Cecka , J. Michael	*23	*32	*41	*44	*04	*17							SSP SSO	
9916	Charlton , Ronald K	*23	*32	*41	*44	*04	*17	*23:01:01	*32:01:01	*41:02:01	*44:03:01	*04:01:01	*17:03	SSP SBT	A*23:17, C*04:82
4492	Charron , Dominiqu							*23:01	*32:01	*41:02	*44:03	*04:01	*17:03	SSP SSO	A*23:54/23:63, A*32:40/32:43/32:44/32:45N/32:47/32:49/32:51/32:53/32:54/32:56N/32:57/32:58/32:59/32:67, B*44:183/44:193/44:198N, C*04:106/04:136/04:148/04:149/04:154/04:156/04:175
3224	Chen , Dong-Feng	*23	*32	*41	*44	*04	*17	*23:01	*32:01	*41:02:01	*44:03:02	*04:09N	*17:03	SSP SSO SBT	
8021	Clark , Brendan	*23	*32	*41	*44	*04	*17			*41:02	*44:03			SSP SSO	A*41:11/41:13/41:27, A*44:13/44:26/44:32
5130	Costeas , Paul A.							*23:01	*32:01	*41:02	*44:03	*04:01	*17:03		C*04:12
779	Daniel , Claude	*23	*32	*41	*44	*04	*17							SSP SSO	
5219	Daniel , Dolly	*23	*32	*41	*44	*04	*17								
1108	DeConinck , Martha	*23	*32	*41	*44	*04	*17								
5214	Eckels/CPMC ,	*23	*32	*41	*44	*04	*17								
3135	Enczmann , J							*23:01	*32:01	*41:02	*44:03	*04:01	*17:01/03		
792	Gandhi , Manish	*23	*32	*41	*44	*04	*17	*23:01	*32:01	*41:02	*44:03	*04:01	*17:03		
8087	Guerra , Q.F.B. Elb	*23	*32	*41	*44	*04	*17							SSO	
810	Hamdi , Nuha							*23:01	*32:01	*41:02	*44:03	*04:01	*17:01/02/03	SSO	A*23:03/23:04, A*32:03/32:05, B*41:11/41:13, B*44:13/44:26, C*04:05/04:09N
1694	Hesse , Nicole	*23	*32	*41	*44	*04	*17							SSP	
2344	Hurley , Hartzman&							*23:01:01	*32:01:01	*41:02:01	*44:03:01	*04:01:01:01	*17:03	OTHER	C*04:01:01:02
794	Jaatinen , Taina	*23	*32	*41	*44	*04	*17	*23:01	*32:01	*41:02	*44:03	*04:01	*17:03	SSP SSO SBT	A*23:17, C*04:30/04:82
8086	Jie , Pan							*23:01	*32:01	*41:02	*44:03	*04:01	*17:03	SBT	
2847	Kihara , Masaaki	*23	*32	*41	*44	*04	*17							SSO	
4337	Kim , Tai-Gyu							*23:01	*32:01	*41:02	*44:03	*04:01	*17:01	SBT	
278	Lee , Jar-How	*23	*32	*41	*44	*04	*17	*23:01	*32:01	*41:02	*44:03	*04:01	*17:03	SSP SSO	
274	Lo , Raymundo W.							*23:01	*32:01	*41:02	*44:03	*04:01	*17:01		
206	McAlack-Hanau ,	*23	*32	*41	*44	*04	*17								
8042	Muncher , Liora	*23	*32	*41	*44	*04	*17	*23:01	*32:01	*41:02	*44:03	*04:01	*17:03	SSP SBT	
54	Pancoska , Carol	*23	*32	*41	*44	*04	*17							SSO	
3966	Permpikul , Vejbaes	*23	*32	*41	*44	*04	*17							SSP	
2400	Phelan , Donna L.	*23	*32	*41	*44	*04	*17	*23:01	*32:01	*41:02	*44:03	*04:01	*17:01:01G	SSP SSO SBT	

Table 5: Individual laboratory results for B-cell #515-Class I															
		Low Resolution						High/Intermediate resolution							
Center	Investigator	HLA-A		HLA-B		HLA-C		HLA-A		HLA-B		HLA-C		METHOD	Other Alleles
3753	Reed , Elaine F.							*23:01	*32:01	*41:02	*44:03	*04:01	*17:01/02/03+	SSP SSO SBT	A*23:03/23:04/*23:17/23:36/23:51/23:64, A*32:03/32:05/32:07/32:13/32:28, B*41:03, B*44:110, C*04:09N/04:30/04:32/04:33/04:82
3519	Renac , Virginie	*23	*32	*41	*44	*04	*17	*23:01	*32:01	*41:02	*44:03	*04:01	*17:03	SSP SBT	A*23:17
4251	Schiller , Jennifer	*23	*32	*41	*44	*04	*17	*23:01:01G	*32:01	*41:02	*44:03	*04:01P	*17:03	SSO SBT	
8068	Shanmugam , Hem	*23	*32	*41	*44	*04	*17							SSP	
8029	Tarigopula , Anil	*23	*32	*41	*44	*04	*17							SSO	
8052	Yanina Marcos , Ci	*23	*32	*41	*44	*04	*17							SSO	

Table 6: Individual laboratory results for B-cell #516-Class II																	
		Low resolution															
Center	Investigator	DRB1		DRB5		DQA1		DQB1		DPA1		DPB1		METHOD	Other Alelles		
5488	Adams , Sharon					*01	*05			NT				SSP SSO SBT			
4691	Al Ajlan , Abdula							*03	*05					SSO			
8070	Chang , Uckjin	*14	*15											SSP			
9916	Charlton , Ronal	*13	*15	5*PRESENT				*03	*05					SSP SBT			
3224	Chen , Dong-Fe	*13	*15	5*01		*01	*05	*03	*05	*02		*01	*05	SSP SSO SBT			
8021	Clark , Brendan	*13	*15	5*01		*01	*05	*03	*05					SSP SSO			
3632	Colombe , Beth	*13	*15	5*01		*01	*05	*03	*05	*02		*01		SSP SSO			
779	Daniel , Claude	*13	*15	5*01		*01	*05	*03	*05	*02		*01		SSP SSO			
5219	Daniel , Dolly	*13	*15					*03	*05								
1108	DeConinck , Ma	*13	*15	5*01		*01	*05	*03	*05	*02		*01	*05		DPB1*118		
3766	Dunn , Paul		*15	5*01		*01	*05	*03	*05								
5214	Eckels/CPMC ,	*13	*15	5*01		*01	*05	*03(DQ7)	*05	*02		*01	*05				
4079	Fort , Marylise	*13	*15					*03	*05					SSP			
792	Gandhi , Manish	*13	*15	5*01		*01	*05	*03	*05	*02	*02	*01					
8087	Guerra , Q.F.B.	*13	*15					*03	*05					SSO			
910	Hahn , Amy B.	*13	*15	5*PRESENT				*03	*05					SSP			
1694	Hesse , Nicole	*13	*15	5*PRESENT				*03	*05					SSP			
8043	Hod , Reut	*13	*15					*03	*05								
771	Israel , Shoshan	*13	*15					*03	*05					SSP SSO			
794	Jaatinen , Taina	*13	*15											SSP SSO SBT			
2847	Kihara , Masaak	*13	*15											SSO			
87	Land , Geoffrey	*13	*15	5*01		*01	*05	*03	*05	*02	*02	*01		SSP SSO SBT			
725	Lardy , N.M.	*13	*15	5*PRESENT		*01	*03	*03	*05					SSP SSO			
278	Lee , Jar-How	*13	*15	5*01		*01	*05	*03	*05	*02		*01	*05	SSP SSO			
6649	Lim , Young Ae	*08	*15	5*PRESENT										SSP			
759	Lopez-Cepero ,	*13	*15	5*01		*01		*03(DQ7)	*05	*02		*01	*05	SSP			
206	McAlack-Hanau	*13	*15	5*01		*01	*05	*03	*05	*01		*02	*04				
8042	Muncher , Liora	*13	*15	5*01		NT	NT	*03	*05	NT	NT	NT	NT	SSP SBT			
54	Pancoska , Carc	*13	*15	5*01		*01	*05	*03	*05	*02		*01	*05	SSO			
2400	Phelan , Donna	*13	*15	5*01		*01	*05	*03	*05			*01	*05	SSP SSO SBT			
8001	Rao , Prakash					*01	*05							SSP SSO			
3519	Renac , Virginie	*13	*15					*03	*05			*01		SSP SBT			
1160	Rosen-Bronson	*13	*15	5*01		*01	*05	*03	*05	*02		*01		SSO SBT			
793	Rubocki , Ronal	*13	*15	5*PRESENT		*01	*05	*03	*05					SSP			
4251	Schiller , Jennife	*13	*15	5*01		*01	*05	*03	*05	*02	*02	*01	*05	SSO SBT			
8068	Shanmugam , H	*13	*15	5*PRESENT				*03	*05					SSP			
8029	Tarigopula , Anil	*13	*15					*03	*05					SSO			
747	Tiercy , Jean-Ma	*13	*15	5*01		*01	*05	*03	*05					SSP SSO SBT			
5451	Tilanus , Marcel	*13	*15	5*PRESENT				*03	*05					SSP SBT			
5642	Varnavidou-Nico	*13	*15	5*01				*03	*05						5*02		
8052	Yanina Marcos ,	*13	*15			*01	*05	*03	*05					SSO			

Table 6b: Individual laboratory results for B-cell #516-Class II										
	Serology									
CTR	DIRNAME	DR13	DR15	DR51	DR52		DQ1	DQ7	OTH1	OTH2
4492	Charron,D.	+	+	+	+		+	+		
910	Hahn,Amy B.	+	+	+	+		+	+		
4908	Kvam,Vonnett	+	+	+			+	+		

Table 7: Individual laboratory results for B-cell #516-Class II

		High/Intermediate resolution											
Center	Investigator	DRB1		DRB5	DQA1		DQB1		DPA1	DPB1		METHOD	Other Alleles
5488	Adams , Sharon	*13:13	*15:02:01	5*01:01			*03:01:01	*05:02:01		*01:01:01	*135:01	SSP SSO SBT	DQA1*01:02/01:11, DQA1*05:05 /05:11
4691	Al Ajlan , Abdulaziz	*13:13	*15:02									SSO	
5462	Arnold , Paula	*13:13	*15:02	5*01:01	NT	NT	*03:01	*05:02	NT	*01:01	*05:01/*135:01	SSP SSO SBT	DQB1*05:34, DRB5*01:15
774	Cecka , J. Michael	*13:13	*15:02	5*01:01	*01:02	*05:05	*03:01	*05:02	*02:02	*01:01	*135:01	SSP SSO	DRB1*15:44/15:47/15:60/15:80N/15:101, DQB1*03:21/03:22/03:24/03:27/03:28/03:29/03:35/03:36/03:42/03:44/03:46/03:47/03:49/03:50/03:51/03:83/03:84N/03:92/03:93/03:94/03:114/03:115/03:116, DQB1*05:14/05:17/05:19/05:26/05:33/05:34/05:35/05:36/05:37/05:46/05:47/05:53/05:57/05:59/05:65, DPA1*02:05
9916	Charlton , Ronald K	*13:13	*15:02:01	5*01:01:01			*03:01:01	*05:02:01				SSP SBT	
4492	Charron , Dominiqu	*13:13	*15:02	5*01:01			*03:01	*05:02	*02:02	*01:01	*05:01/*135:01/*+	SSP SSO	DQB1*03:82/03:92/03:93/03:94/03:114/03:115/03:116, DQB1*05:53/05:57/05:59/05:65, DPB1*326:01/327:01/346:01
3224	Chen , Dong-Feng	*13:13	*15:02:01	5*01:01	*01:02:01G	*05:01:01G	*03:01:01G	*05:02:01	*02:02	*01:01	*05:01	SSP SSO SBT	
8021	Clark , Brendan	*13:13	*15:02	5*01:01	*01:02	*05:05	*03:01	*05:02		*01:01	*135:01	SSP SSO	DRB1*15:80N, DQA1*01:08/01:09/01:11, DQA1*05:09/05:11
3632	Colombe , Beth W.	*13:13	*15:02	5*01:01	*01:02	*05:05	*03:01	*05:02	*02:02	*01:01	*135:01	SSP SSO	
5130	Costeas , Paul A.	*13:13	*15:02	5*01:01	*01:02	*05:05	*03:01	*05:02					DQA1*05:01
779	Daniel , Claude	*13:13			*01:02	*05:05	*03:01		*02:01	*01:01	*135:01	SSP SSO	DRB1*13:154, DPA1*02:05
3766	Dunn , Paul								*02:02	*01:01	*05:01		
5214	Eckels/CPMC ,						*03:01				*05:01:01G		
3135	Enczmann , J	*13:13	*15:02	5*01:01			*03:01	*05:02		*01:01	*135:01		
762	Fischer , Gottfried	*13:13	*15:02	5*01:01	*01:02	*05:05	*03:01	*05:02		*01:01	*05:01/*135:01	SSP SSO SBT	DQB1*05:47
4079	Fort , Marylise									*01:01	*135:01	SSP	DPB1*05:01
792	Gandhi , Manish	*13:13	*15:02		*01:02	*05:05	*03:01	*05:02		*01:01	*135:01		
810	Hamdi , Nuha	*13:13	*15:02	5*01:01	*01:02	*05:05	*03:01	*05:02				SSO	DQA1*05:09/05:11, DQB1*03:27/03:28, DQB1*05:17/05:19, DRB5*01:15
8043	Hod , Reut	*13:13	*15:02		*01:02	*05:05	*03:01	*05:02					
2344	Hurley , Hartzman&	*13:13	*15:02:01		*01:02:01	*05:05:01	*03:01:01:01	*05:02:01	*02:02:02	*01:01:01	*05:01:01/*135:01	OTHER	DQB1*03:01:01:02/03:01:01:03
771	Israel , Shoshana	*13:13	*15:02				*03:01	*05:02				SSP SSO	
794	Jaatinen , Taina	*13:13	*15:02	5*01:01	*01:02	*05:05	*03:01	*05:02	*02:02	*01:01	*05:01/*135:01	SSP SSO SBT	DQA1*01:08/01:09/01:11, DQA1*05:09/05:11
8086	Jie , Pan	*13:13	*15:02		*01:02	*05:05	*03:01	*05:02	*02:02	*01:01	*135:01	SBT	
4337	Kim , Tai-Gyu	*13:13	*15:02				*03:01	*05:02		*01:01	*135:01	SBT	
87	Land , Geoffrey A.	*13:13	*15:02	5*01:01	*01:02	*05:05	*03:01	*05:02	*02:02	*01:01	*135:01	SSP SSO SBT	DPB1*05:01
278	Lee , Jar-How	*13:13	*15:02	5*01:01	*01:02	*05:05	*03:01	*05:02	*02:02	*01:01	*05:01	SSP SSO	

Table 7: Individual laboratory results for B-cell #516-Class II													
		High/Intermediate resolution											
Center	Investigator	DRB1		DRB5	DQA1		DQB1		DPA1	DPB1		METHOD	Other Alleles
274	Lo , Raymundo W.	*13:13	*15:02		*01:02	*05:05	*03:01	*05:05	*02:02	*01:01	*05:01		
8042	Muncher , Liora	*13:13	*15:02	5*01:01	NT	NT	*03:01	*05:02	NT	NT	NT	SSP SBT	
3966	Permpikul , Vejbaes	*13:13	*15:02	5*01:01			*03:01	*05:02				SSP	
2400	Phelan , Donna L.	*13:13	*15:02		*01:02	*05:05	*03:01	*05:02		*01:01:02G	*05:01:01G	SSP SSO SBT	
8001	Rao , Prakash	*13:13	*15:02	5*01:01			*03:01	*05:02		*01:01	*05:01	SSP SSO	
3753	Reed , Elaine F.	*13:13	*15:02	5*01:01	*01:02:01G	*05:05	*03:01	*05:02	*02:02	*01:01	*135:01	SSP SSO SBT	DRB1*13:154, DRB1*15:11, DQB1*03:29/03:73, DRB5*01:15, DQB1*05:05, DQA1*05:09/05:11
3519	Renac , Virginie	*13:13	*15:02	5*01:01	*01:02	*05:05	*03:01	*05:02	*02:02	*01:01	*135:01	SSP SBT	DQA1*01:09, DQA1*05:01
1160	Rosen-Bronson , Sa	*13:13	*15:02	5*01:01					*02:02	*01:01	*135:01	SSO SBT	DRB1*13:154, DRB1*15:11, DRB5*01:15
793	Rubocki , Ronald									*01:01	*135:01	SSP	
4251	Schiller , Jennifer	*13:13	*15:02				*03:01	*05:02		*01:01	*05:01:01G	SSO SBT	
747	Tiercy , Jean-Marie	*13:13	*15:02	5*01:01	*01:02	*05:05	*03:01	*05:02		*01:01:01G	*05:01:01G	SSP SSO SBT	DQA1*01:08/01:09, DQA1*01:11, DQA1*05:09/05:11
5451	Tilanus , Marcel G.	*13:13	*15:02:01									SSP SBT	
5642	Varnavidou-Nicolaid	*13:13	*15:02				*03:01	*05:02					
3511	Zeevi , Adriana	*13:13	*15:02	5*01:01	*01:02	*05:05	*03:01	*05:02		*01:01	*05:01P	SSP SSO	

Table 8: Individual laboratory results for B-cell #516-Class I															
		Low Resolution						High resolution							
Center	Investigator	HLA-A		HLA-B		HLA-C		HLA-A		HLA-B		HLA-C		METHOD	Other Alleles
5488	Adams , Sharon	*11	*24			*01	*08			*27:06	*48:01:01			SSP SSO SBT	A*11:01/11:12/11:19/11:27/11:88/11:117/11:119:01, A*24:02/24:07/24:10:01/24:21:01/24:50/24:235/24:260, C*01:02/01:43/01:85, C*08:01:01/08:16:01/08:22/08:99/08:102
4691	Al Ajlan , Abdulaziz	*11	*24	*27	*48	*01	*08							SSO	
5462	Arnold , Paula							*11:01	*24:02	*27:06	*48:01	*01:02	*08:01	SSP SSO SBT	
774	Cecka , J. Michael	*11	*24	*27	*48	*01	*08							SSP SSO	
9916	Charlton , Ronald K	*11	*24	*27	*48	*01	*08	*11:01	*24:02	*27:06	*48:01:01	*01:02:01	*08:01:01	SSP SBT	
4492	Charron , Dominiqu							*11:01	*24:02	*27:06	*48:01	*01:02	*08:01	SSP SSO	A*11:91:01/11:91:02/11:100/11:114/11:115N/11:117/11:120/11:125/11:127N/11:132/11:133/11:135/11:136/11:137N/11:138, A*24:154/24:193/24:195/24:202/24:209/24:212/24:217/24:221/24:223, B*48:32/48:33/48:35, C*01:85/01:88/01:93/01:94/01:96/01:98N/01:100, C*08:78/08:79/08:84/08:85/08:89N/08:95/08:99/08:109
3224	Chen , Dong-Feng	*11	*24	*27	*48	*01	*08	*11:01:01	*24:02:01G	*27:06	*48:01:01	*01:02:01G	*08:01:01G	SSP SSO SBT	
8021	Clark , Brendan	*11	*24	*27	*48	*01	*08							SSP SSO	
5130	Costeas , Paul A.							*11:01	*24:02	*27:06	*48:01	*01:02	*08:01		A*11:09, C*01:28/01:31
779	Daniel , Claude	*11	*24	*27	*48	*01	*08							SSP SSO	
5219	Daniel , Dolly	*11	*24	*27	*48	*01	*08								
1108	DeConinck , Martha	*11	*24	*27	*48	*01	*08								
5214	Eckels/CPMC ,	*11	*24	*27	*48	*01	*08								
3135	Enczmann , J							*11:01	*24:02	*27:06	*48:01	*01:02	*08:01		
792	Gandhi , Manish	*11	*24	*27	*48	*01	*08	*11:01	*24:02	*27:06	*48:01	*01:02	*08:01		
8087	Guerra , Q.F.B. Elb	*11	*24	*27	*48	*01	*08							SSO	
810	Hamdi , Nuha							*11:12	*24:02	*27:06	*48:01	*04:01	*17:01	SSO	A*11:159, A*24:61, B*27:07/27:09, B*48:09/48:11, C*04:05/04:09N, C*17:02/17:03
1694	Hesse , Nicole	*11	*24	*27	*48	*01	*08							SSP	
2344	Hurley , Hartzman&							*11:01:01	*24:02:01:01	*27:06	*48:01:01	*01:02:01	*08:01:01	OTHER	
794	Jaatinen , Taina	*11	*24	*27	*48	*01	*08	*11:01	*24:02	*27:06	*48:01	*01:02	*08:01	SSP SSO SBT	C*08:22
8086	Jie , Pan							*11:01	*24:02	*27:06	*48:01	*01:02	*08:01	SBT	
2847	Kihara , Masaaki	*11	*24	*27	*48	*01	*08							SSO	
4337	Kim , Tai-Gyu							*11:01	*24:02	*27:06	*48:01	*01:02	*08:01	SBT	
278	Lee , Jar-How	*11	*24	*27	*48	*01	*08	*11:01	*24:02	*27:06	*48:01	*01:02	*08:01	SSP SSO	
274	Lo , Raymundo W.							*11:01	*24:02	*27:06	*48:01	*01:02	*08:01		
206	McAlack-Hanau ,	*11	*24	*27	*48	*01	*08								
8042	Muncher , Liora	*11	*24	*27	*48	*01	*08	*11:01	*24:02	*27:06	*48:01	*01:02	*08:01	SSP SBT	

Table 8: Individual laboratory results for B-cell #516-Class I															
		Low Resolution						High resolution							
Center	Investigator	HLA-A		HLA-B		HLA-C		HLA-A		HLA-B		HLA-C		METHOD	Other Alleles
54	Pancoska , Carol	*11	*24	*27	*48	*01	*08							SSO	
3966	Permpikul , Vejbaes	*11	*24	*27	*48	*01	*08							SSP	
2400	Phelan , Donna L.	*11	*24	*27	*48	*01	*08	*11:01	*24:02	*27:06	*48:01	*01:02	*08:01	SSP SSO SBT	
3753	Reed , Elaine F.							*11:01	*24:02	*27:06	*48:01	*01:02	*08:01	SSP SSO SBT	A*11:04/11:12/11:19/11:27/11:39/11:88/11:117/11:119/11:178, A*24:03/24:07/24:10/24:19/24:21/24:46/24:50 /24:235/24:260, C*01:43/01:64/01:85, C*08:16/08:22/08:80/08:99/08:102
3519	Renac , Virginie	*11	*24	*27	*48	*01	*08	*11:01	*24:02	*27:06	*48:01	*01:02	*08:01	SSP SBT	
4251	Schiller , Jennifer	*11	*24	*27	*48	*01	*08	*11:01	*24:02	*27:06	*48:01	*01:02:01G	*08:01:01G	SSO SBT	
8068	Shanmugam , Hem	*11	*24	*27	*48	*01	*08							SSP	
8029	Tarigopula , Anil	*11	*24	*27	*48	*01	*08							SSO	
8052	Yanina Marcos , Cir	*11	*24	*27	*48	*01	*08							SSO	

Cell Exchange #387

The results for Cell Exchange #387 are summarized in Table 9 and Table 10. Molecular typing results for individual laboratories are listed in Tables 11 -14 for each sample and individual serology results for each sample are listed in Table 15.

Cell 1545. The consensus type for this sample from a Hispanic donor is A*01:02(A1)-A*24:02(A24)-B*40:02(B61)-B*49:01(B49)-C*03:05(Cw3)-C*07:01(Cw7). The probable associations present in this cell are A*01:02-B*49:01-C*07:01 and A*24:02-B*40:02-C*03:05, with respective frequencies of 0.00152 and 0.00231, in Hispanics. The B*40:02-C*03:05 haplotype in this cell was observed in 2 other previous exchange samples, cell 1474 and cell 1531, also from Hispanic donors.

This cell was previously typed as cell 1498 (2013), as noted by Claas. In this present typing, Cw3 was detected by 52%, with 2 labs assigning Cw10. Cw10 was confirmed as C*03:05 by 84% of labs reporting at high resolution. Cw7 (52%) was reported as the second C-locus type and confirmed as C*07:01 (100%). C*07:01:01 was reported by 3 labs. A1 (100%) and A24 (96%) were the reported A-locus types, with DNA assigning A*01:02 (94%) and A*24:02 (100%). B61 (76%) was reported as the split of B40, and B49 (92%) was reported as the split of B21. B*40:02 (95%) and B*49:01 (100%) were assigned by DNA, with 4 labs assigning B*40:02:01 and 2 labs reporting B*49:01:01.

Cell 1546. The consensus type for this sample from a Filipino donor is A*24:07(A24)-A*24:33-B*38:02(B38)-B*51:06(B51)-C*07:02(Cw7)-C*12:04. The offspring of this donor were previously studied in the exchange as cell 1491, cell 1426, and extract 590. From this family data, the haplotypes in this cell were determined to be A*24:07-B*38:02-C*07:02 and A*24:33-B*51:06-C*12:04.

This cell was typed a number (n=5) times in the exchange as cells 1427 (2011), 1331 (2008), 1278 (2006), 1231 (2005), and 1214 (2004), as correctly identified by Claas. In this present retyping, A24 was detected by 96%, with DNA assigning A*24:07 (100%) and A*24:33 (88%). A*24:07:01 was assigned by 4 labs. B*38:02 (100%) and B*51:06 (94%) were the reported B-locus types, with 6 labs assigning B*38:02:01 and 8 labs assigning B*51:06:01. B38 (100%) and B51 (96%) were reported by serology. Rees noted the B51 reactivity in this sample was short. C*07:02 and C*12:04 were each assigned by 96%, as the C-locus types, with 3 labs assigning C*07:02:01 and 7 labs assigning C*12:04:02. Cw7 (52%) was reported by serology. Additional reactivity to Cw6 antisera was also reported by 4 labs.

Cell 1547. The consensus type for this sample from a Hispanic donor is A*02:01(A2)-A*68:01(A68)-B*40:20(B61)-B*51:02(B51)-C*03:04(Cw3)-C*08:01(Cw8). Likely associations in this cell may be A*02:01-B*51:02-C*08:01 and A*68:01-B*40:20-C*03:04, with respective frequencies of 0.00157 and 0.00051, in Hispanics.

This sample was previously typed as cells 1473 (2012), 1415 (2010), and 1386 (2010), as astutely noted by Claas and Kvam. In this present retyping, B40 was reported by 96%, with 70% of labs assigning B61. Askar commented on the reaction pattern of B61 in this cell as being different from that of cell 1545. B61 was confirmed by DNA as B*40:20 (96%). The other B-locus allele, B51, was reported by 96%, with 17% of labs assigning the variant B5102. B*51:02 was reported by 100% of labs reporting at high resolution. B*51:02:01 was reported by 9 labs. Cw3 (Cw10) was reported by 61% and Cw8 by 35%. C*03:04 (94%) and C*08:01 (100%) were reported by DNA, with 4 labs assigning C*03:04:01 and 3 labs reporting C*08:01:01.

Cell 1548. The consensus type for this sample from a Caucasian donor is A*23:01(A23)-A*29:01(A29)-B*35:02(B35)-B*49:01(B49)-C*04:01(Cw4)-C*07:01(Cw7). The probable associations in this cell are A*23:01-B*49:01-C*07:01 and A*29:01-B*35:02-C*04:01, with respective frequencies of 0.00369 and 0.00012, in Caucasians. The B*35:02-C*04:01 association in this cell has been observed in 3 other exchange samples, cells 867, 897, and 1482.

A23 and A29 were reported in complete consensus and confirmed as A*23:01 (100%) and A*29:01 (100%). B35 (100%) and B49 (91%) were the B-locus types, with DNA assigning B*35:02 (100%) and B*49:01 (100%). Cw4 and Cw7 were assigned by 61% and 57%, respectively. C*04:01 and C*07:01 were each assigned by 94% of labs reporting at high resolution.

Table 9. Summary of the 387th Cell Exchange (Cell #1545-1548)

DNA typing

Cell 1545		Cell 1546		Cell 1547		Cell 1548	
25 labs Low;17 labs High/Inter	% (n)	25 labs Low;16 labs High	% (n)	24 labs Low;15 labs High	% (n)	24 labs Low;17 labs High	% (n)
A*01:02	94(16)	A*24:07:01	25(4)	A*02:01:01	20(3)	A*23:01:01G	12(2)
A*01:01/02+	6 (1)	A*24:07	75(12)	A*02:01	80(12)	A*23:01P	12(2)
A*01	100(25)	A*24	100(25)	A*02	100(24)	A*23:01	76(13)
						A*23	100(24)
26 labs Low;16 labs High	% (n)	17 labs High	% (n)	24 labs Low;15 labs High	% (n)	24 labs Low;17 labs High	% (n)
A*24:02	100(16)	A*24:03:01G	6 (1)	A*68:01:02G	13(2)	A*29:01:01:01	12(2)
A*24	100(26)	A*24:33	88(15)	A*68:01	87(13)	A*29:01:01G	6 (1)
		*A*24:03*	6 (1)	A*68	100(24)	A*29:01	82(14)
						A*29	100(24)
26 labs Low;19 labs High	% (n)	26 labs Low;15 labs High	% (n)	23 labs Low;23 labs High	% (n)	24 labs Low;17 labs High	% (n)
B*40:02:01	21(4)	B*38:02:01	40(6)	B*40:20	96(22)	B*35:02:01	24(4)
B*40:02	74(14)	B*38:02	60(9)	*B*40:03*	4 (1)	B*35:02	76(13)
*B*40:35*	5 (1)	B*38	100(26)	B*40(B61)	9 (2)	B*35	100(24)
B*40(B61)	12 (3)			B*40	91(21)		
B*40	88(23)						
26 labs Low;16 labs High	% (n)	26 labs Low;16 labs High	% (n)	24 labs Low;17 labs High	% (n)	24 labs Low;17 labs High	% (n)
B*49:01:01	13(2)	B*51:06:01	50(8)	B*51:02:01	53(9)	B*49:01:01	6 (1)
B*49:01	87(14)	B*51:06	44(7)	B*51:02	47(8)	B*49:01	94(16)
B*49	100(26)	*B*51:04*	6 (1)	B*51	100(24)	B*49	100(24)
		B*51	100(26)				
24 labs Low;19 labs High/Inter	% (n)	25 labs Low;15 labs High	% (n)	23 labs Low;18 labs High/Inter	% (n)	23 labs Low;16 labs High	% (n)
C*03:05	84(16)	C*07:02:01	20(3)	C*03:04:01	22(4)	C*04:01:01G	13(2)
*C*03:02*	11(2)	C*07:02:01G	7 (1)	C*03:04	72(13)	C*04:01P	6 (1)
C*03:02/05	5(1)	C*07:02P	7 (1)	C*03:02/04+	6 (1)	C*04:01	75(12)
C*03(Cw10)	12(3)	C*07:02	60(9)	C*03(Cw10)	13(3)	*C*04:54*	6 (1)
C*03	88(21)	*C*07:315*	7 (1)	C*03	87(20)	C*04	100(23)
		C*07	100(25)				
25 labs Low;15 labs High Res	% (n)	25 labs Low;14 labs High/Inter	% (n)	23 labs Low;15 labs High	% (n)	23 labs Low;16 labs High	% (n)
C*07:01:01	20(3)	C*12:04:02	50(7)	C*08:01:01	20(3)	C*07:01:01G	13(2)
C*07:01:01G	7 (1)	C*12:04	43(6)	C*08:01:01G	13(2)	C*07:01P	6 (1)
C*07:01P	7 (1)	C*12:03/04+	7 (1)	C*08:01P	7 (1)	C*07:01	75(12)
C*07:01	66(10)	C*12	100(25)	C*08:01	60(9)	*C*04:58*	6 (1)
C*07	100(25)			C*08	100(23)	C*07	100(23)

Table 10. Summary of the 387th Cell Exchange (Cell #1545-1548)

Serological typing

(Hispanic)	
Cell 1545	
(25 Samples Typed)	
A1	100.0%
A24	96.0%
	[96.0%]
B61	76.0%
B40	16.0%
	[92.0%]
B49	92.0%
B21	8.0%
	[100.0%]
Cw3	44.0%
Cw10	8.0%
	[52.0%]
Cw7	52.0%
Bw4	84.0%
Bw6	84.0%
Others Found	
B5	4.0%
Cw4	4.0%
A80	4.0%
B4005	4.0%
B60	4.0%
B48	4.0%

(Filipino)	
Cell 1546	
(25 Samples Typed)	
A24	96.0%
	[96.0%]
B38	100.0%
	[100.0%]
B51	96.0%
B5	4.0%
	[100.0%]
Cw7	52.0%
Bw4	84.0%
Others Found	
Cw6	16.0%
A32	8.0%
B44	4.0%
B37	4.0%
A23	4.0%

(Hispanic)	
Cell 1547	
(23 Samples Typed)	
A2	95.7%
	[95.7%]
A68	69.6%
A28	26.1%
	[95.7%]
B61	69.6%
B40	26.1%
	[95.7%]
B51	78.3%
B5102	17.4%
	[95.7%]
Cw3	47.8%
Cw10	13.0%
	[60.9%]
Cw8	34.8%
Bw4	82.6%
Bw6	82.6%
Others Found	
B35	4.3%
B53	4.3%
A33	4.3%
B60	4.3%

(Caucasian)	
Cell 1548	
(23 Samples Typed)	
A23	100.0%
	[100.0%]
A29	100.0%
	[100.0%]
B35	100.0%
B49	91.3%
B21	8.7%
	[100.0%]
Cw4	60.9%
	[60.9%]
Cw7	56.5%
Bw4	82.6%
Bw6	82.6%
Others Found	
B52	4.3%
B53	4.3%

Table 11. Individual laboratory results for Cell #1545

		Low Resolution						High/Intermediate Resolution							
Center	**Investigator**	**HLA-A**		**HLA-B**		**HLA-C**		**HLA-A**		**HLA-B**		**HLA-C**		**Method**	**Other Alleles**
5462	Arnold , Paula							*01:02	*24:02	*40:02	*49:01	*03:05	*07:01	SSO SBT	
16	Askar , Medhat Z.	*01	*24	*40	*49	*03	*07	*01:02	*24:02	*40:02:01	*49:01	*03:05	*07:01:01	SSO SBT	C*03:27, C*07:40
8038	Cao , Kai							*01:02	*24:02	*40:02:01	*49:01	*03:05	*07:01P	SSO SBT	
774	Cecka , J. Michael		*24	*40	*49		*07	*01:02				*03:05		SSP	C*03:25/03:143/03:27/03:167
8070	Chang , Uckjin	*01	*24	*40	*49	*03	*07							SSP	
4492	Charron , Dominiqu	*01	*24	*40	*49	*03	*07			*40:02		*03:02/05		SSP	B*40:05/40:09/40:27
798	Claas , F.H.J.							*01:02	*24:02	*40:02:01	*49:01	*03:05	*07:01:01	SBT	
3632	Colombe , Beth W.	*01	*24	*40	*49	*03	*07	*01:02	*24:02	*40:35	*49:01	*03:05	*07:01	SSP SSO	
779	Daniel , Claude	*01	*24	*40	*49	*03	*07			*40:02		*03:02		SSP SSO	
3766	Dunn , Paul	*01	*24	*40	*49	*03	*07							SSO	
5214	Eckels/CPMC ,	*01	*24	*40(B61)	*49	*03(Cw10)	*07							SSO	
762	Fischer , Gottfried	*01	*24	*40	*49	*03	*07							SSP SSO SBT	
4079	Fort , Marylise	*01	*24	*40	*49	*03	*07							SSP SSO	
3545	Goldstein , Steven							*01:02	*24:02	*40:02	*49:01	*03:05	*07:01	SSP SSO SBT	C*07:06/07:18/07:343
810	Hamdi , Nuha							*01:01/02+	*24:02	*40:02	*49:01	*03:02	*07:01	SSO	A*24:05, B*40:35/40:56, B*49:06/49:12, C*07:02/07:05
8043	Hod , Reut	*01	*24	*40	*49	*03	*07	*01:02	*24:02	*40:02	*49:01	*03:05	*07:01		
771	Israel , Shoshana	*01	*24	*40	*49	*03	*07	*01:02	*24:02	*40:02	*49:01	*03:05	*07:01	SSP SSO	
725	Lardy , N.M.	*01	*24	*40	*49	*03	*07							SSO	
745	Latham , Katy							*01:02	*24:02	*40:02	*49:01	*03:05	*07:01:01	SSP SSO SBT	
278	Lee , Jar-How	*01	*24	*40	*49	*03	*07	*01:02	*24:02	*40:02	*49:01:01	*03:05	*07:01	SSP SSO	
6649	Lim , Young Ae	*01	*24	*40	*49									SSP	
731	Loewenthal , Ron							*01:02	*24:02	*40:02	*49:01	*03:05	*07:01		
759	Lopez-Cepero , Ma	*01	*24	*40(B61)	*49	*03(Cw10)	*07							SSP	
54	Pancoska , Carol	*01	*24	*40	*49	*03	*07							SSO	
8001	Rao , Prakash	*01	*24	*40(B61)	*49	*03(Cw10)	*07							SSP SSO	
3625	Rees , Tracey	*01	*24	*40	*49	*03	*07	*01:02	*24:02	*40:02	*49:01	*03:05	*07:01		
1160	Rosen-Bronson , Sa	*01	*24	*40	*49	*03	*07	*01:02	*24:02	*40:02	*49:01	*03:05		SSO SBT	C*03:27
793	Rubocki , Ronald	*01	*24	*40	*49	*03	*07							SSP	
4251	Schiller , Jennifer	*01	*24	*40	*49	*03	*07	*01:02	*24:02	*40:02	*49:01	*03:05	*07:01:01G	SSO SBT	
3808	Thornton , Alycia	*01	*24	*40	*49	*03	*07							SSP SBT	
747	Tiercy , Jean-Marie	*01	*24	*40	*49	*03	*07	*01:02	*24:02	*40:02:01	*49:01:01	*03:05	*07:01	SSP SSO SBT	B*49:01:04
5642	Varnavidou-Nicolaid	*01	*24	*40	*49	*03	*07							SSP	
3186	Watson , Narelle	*01	*24	*40	*49	*03	*07							SSO	B*50

Table 12. Individual laboratory results for Cell #1546															
		Low Resolution						High/Intermediate Resolution							
Center	**Investigator**	**HLA-A**		**HLA-B**		**HLA-C**		**HLA-A**		**HLA-B**		**HLA-C**		**Method**	**Other Alleles**
5462	Arnold , Paula							*24:07	*24:33	*38:02	*51:06	*07:02	*12:04	SSO SBT	
16	Askar , Medhat Z.	*24	*24	*38	*51	*07	*12	*24:07:01	*24:33	*38:02:01	*51:06:01	*07:02:01	*12:04:02	SSO SBT	C*07:76:01, C*12:03:01
8038	Cao , Kai							*24:07:01	*24:33	*38:02:01	*51:06:01	*07:02P	*12:04:02	SSO SBT	
774	Cecka , J. Michael			*38	*51	*07	*12	*24:07	*24:33					SSP	A*24:112/24:131/ 24:288
8070	Chang , Uckjin	*24	*24	*38	*51	*07	*12							SSP	
4492	Charron , Dominiqu	*24		*38	*51	*07	*12				*51:06			SSP	
798	Claas , F.H.J.							*24:07:01	*24:33	*38:02:01	*51:06:01	*07:02:01	*12:04:02	SBT	
3632	Colombe , Beth W.	*24	*24	*38	*51	*07	*12	*24:07	*24:33	*38:02	*51:06	*07:02	*12:04	SSP SSO	
779	Daniel , Claude	*24	*24	*38	*51	*07	*12		*24:03					SSP SSO	
3766	Dunn , Paul	*24	*24	*38	*51	*07	*12							SSO	
5214	Eckels/CPMC ,	*24	*24	*38	*51	*07	*12		*24:03:01G					SSO	
762	Fischer , Gottfried	*24		*38	*51	*07	*12							SSP SSO SBT	
4079	Fort , Marylise	*24		*38	*51	*07	*12							SSP SSO	
3545	Goldstein , Steven									*38:02	*51:06	*07:02	*12:04	SSP SSO SBT	C*07:50/07:349
810	Hamdi , Nuha							*24:07	*24:33	*38:02	*51:04	*07:315	*12:03/04+	SSO	A*24:22/24:33/24:112/24:131, B*38:15/38:18, B*51:06 /51:46
8043	Hod , Reut	*24	*24	*38	*51	*07	*12								
771	Israel , Shoshana	*24	*24	*38	*51	*07	*12	*24:07	*24:33	*38:02	*51:06	*07:02	*12:04	SSP SSO	
725	Lardy , N.M.	*24		*38	*51	*07	*12							SSO	
745	Latham , Katy							*24:07	*24:33	*38:02:01	*51:06:01	*07:02	*12:04	SSP SSO SBT	C*07:159/07:160/ C07:167
278	Lee , Jar-How	*24	*24	*38	*51	*07	*12	*24:07	*24:33	*38:02:01	*51:06:01	*07:02:01	*12:04:02	SSP SSO	
6649	Lim , Young Ae	*24		*38	*51									SSP	
731	Loewenthal , Ron							*24:07	*24:33	*38:02	*51:06	*07:02			
759	Lopez-Cepero , May	*24	*24	*38	*51	*07	*12							SSP	
54	Pancoska , Carol	*24	*24	*38	*51	*07	*12							SSO	
8001	Rao , Prakash	*24		*38	*51	*07	*12							SSP SSO	
3625	Rees , Tracey	*24	*24	*38	*51	*07	*12	*24:07	*24:33	*38:02	*51:06:01	*07:02	*12:04:02		
1160	Rosen-Bronson , Sa	*24		*38	*51	*07	*12	*24:07	*24:33	*38:02	*51:06			SSO SBT	
793	Rubocki , Ronald	*24		*38	*51	*07	*12							SSP	
4251	Schiller , Jennifer	*24	*24	*38	*51	*07	*12	*24:07	*24:33	*38:02	*51:06:01	*07:02:01G	*12:04:02	SSO SBT	
3808	Thornton , Alycia	*24	*24	*38	*51	*07	*12	*24:07				*07:02	*12:04	SSP SBT	
747	Tiercy , Jean-Marie	*24	*24	*38	*51	*07	*12	*24:07:01	*24:33	*38:02:01	*51:06:01	*07:02	*12:04:02	SSP SSO SBT	
5642	Varnavidou-Nicolaid	*24		*38	*51	*07	*12							SSP	
3186	Watson , Narelle	*24	*24	*38	*51	*07	*12							SSO	

Table 13. Individual laboratory results for Cell #1547

		Low Resolution						High/Intermediate Resolution							
Center	**Investigator**	**HLA-A**		**HLA-B**		**HLA-C**		**HLA-A**		**HLA-B**		**HLA-C**		**Method**	**Other Alleles**
5462	Arnold , Paula							*02:01	*68:01	*40:20	*51:02	*03:04	*08:01	SSO SBT	C*03:64, C*08:105
16	Askar , Medhat Z.	*02	*68	*40	*51	*03	*08	*02:01	*68:01:02G	*40:20	*51:02:01	*03:04:01	*08:01:01	SSO SBT	A*02:22/02:43N/02:246/02:334 , A*68:08/68:11N/ 68:104:01/ 68:105/68:01:25, B*40:159, B*51:59, C*03:35/03:64:01/03:92, C*08:41/08:44/08:105
8038	Cao , Kai							*02:01:01	*68:01:02G	*40:20	*51:02:01	*03:04:01	*08:01P	SSO SBT	
774	Cecka , J. Michael	*02	*68		*51	*03	*08			*40:20				SSP	
8070	Chang , Uckjin	*02	*68	*40	*51	*03	*08							SSP	
4492	Charron , Dominiqu	*02	*68	*40	*51	*03	*08			*40:20		*03:02/04+		SSP	
798	Claas , F.H.J.							*02:01:01	*68:01	*40:20	*51:02:01	*03:04:01	*08:01:01	SBT	
3632	Colombe , Beth W.	*02	*68	*40	*51	*03	*08	*02:01	*68:01	*40:20	*51:02	*03:04	*08:01	SSP SSO	
779	Daniel , Claude	*02	*68	*40	*51	*03	*08			*40:20		*03:04		SSP SSO	
3766	Dunn , Paul	*02	*68	*40	*51	*03	*08							SSO	
5214	Eckels/CPMC ,	*02	*68	*40(B61)	*51	*03(Cw10)	*08							SSO	
762	Fischer , Gottfried							*02:01	*68:01	*40:20	*51:02:01	*03:04	*08:01	SSP SSO SBT	A*02:01:01:02L, C*08:22/ *08:99/*08:102
4079	Fort , Marylise	*02	*68	*40	*51	*03	*08	*02:01	*68:01	*40:20	*51:02:01	*03:04	*08:01	SSP SSO	
3545	Goldstein , Steven							*02:01	*68:01	*40:20	*51:02	*03:04	*08:01	SSP SSO SBT	C*08:22/08:99/08:102
810	Hamdi , Nuha							*02:01	*68:01	*40:20	*51:02	*03:04	*08:01	SSO	A*02:01L/68:07/68:08, B*40:159, B*51:59/51:70, C*03:47/03:64, C*08:08/08:20
8043	Hod , Reut	*02	*68	*40	*51	*03	*08								
771	Israel , Shoshana	*02	*68	*40	*51	*03	*08	*02:01	*68:01	*40:20	*51:02	*03:04	*08:01:01G	SSP SSO	
725	Lardy , N.M.	*02	*68	*40	*51	*03	*08							SSO	
745	Latham , Katy							*02:01	*68:01	*40:20	*51:02:01	*03:04	*08:01	SSP SSO SBT	C*08:102
278	Lee , Jar-How	*02	*68	*40	*51	*03	*08	*02:01:01	*68:01	*40:20	*51:02:01	*03:04:01	*08:01:01	SSP SSO	
6649	Lim , Young Ae	*02	*68	*40	*51									SSP	
731	Loewenthal , Ron							*02:01	*68:01	*40:03	*51:02	*03:04	*08:01		
759	Lopez-Cepero , May	*02	*68	*40(B61)	*51	*03(Cw10)	*08							SSP	
54	Pancoska , Carol	*02	*68	*40	*51	*03	*08							SSO	
8001	Rao , Prakash	*02	*68	*40	*51	*03(Cw10)	*08			*40:20				SSP SSO	
3625	Rees , Tracey	*02	*68	*40	*51	*03	*08	*02:01	*68:01	*40:20	*51:02:01	*03:04	*08:01		A*68:11N
1160	Rosen-Bronson , Sa	*02	*68	*40	*51	*03	*08			*40:20	*51:02			SSO SBT	B*40:159, B*51:59
793	Rubocki , Ronald	*02	*68	*40	*51	*03	*08			*40:20				SSP	
4251	Schiller , Jennifer	*02	*68	*40	*51	*03	*08	*02:01	*68:01	*40:20	*51:02:01	*03:04	*08:01:01G	SSO SBT	
3808	Thornton , Alycia	*02	*68	*40	*51	*03	*08			*40:20	*51:02	*03:04		SSP SBT	
747	Tiercy , Jean-Marie	NT												SSP SSO SBT	
5642	Varnavidou-Nicolaid	*02	*68	*40	*51	*03	*08							SSP	
3186	Watson , Narelle	*02	*68	*40	*51	*03	*08			*40:20				SSO	

Table 14. Individual laboratory results for Cell #1548

		Low Resolution						High Resolution							
Center	**Investigator**	**HLA-A**		**HLA-B**		**HLA-C**		**HLA-A**		**HLA-B**		**HLA-C**		**Method**	**Other Alleles**
5462	Arnold , Paula							*23:01P	*29:01	*35:02	*49:01	*04:01	*07:01	SSO SBT	
16	Askar , Medhat Z.	*23	*29	*35	*49	*04	*07	*23:01:01G	*29:01:01:01	*35:02:01	*49:01	*04:01	*07:01	SSO SBT	A*23:17, C*04:15:02/04:29/ 04:54/ 04:112/04:116, C*07:09/07:27:01/07:28 /07:73 /07:108:02
8038	Cao , Kai							*23:01P	*29:01:01G	*35:02:01	*49:01	*04:01:01G	*07:01P	SSO SBT	
774	Cecka , J. Michael	*23	*29	*35	*49	*04	*07							SSP	
8070	Chang , Uckjin	*23	*29	*35	*49	*04	*07							SSP	
4492	Charron , Dominiqu	*23	*29	*35	*49	*04	*07							SSP	
798	Claas , F.H.J.							*23:01	*29:01:01:01	*35:02:01	*49:01:01	*04:01	*07:01	SBT	A*23:17/23:69, C*04:82, C*07:343
3632	Colombe , Beth W.	*23	*29	*35	*49	*04	*07	*23:01	*29:01	*35:02	*49:01	*04:01	*07:01	SSP SSO	
779	Daniel , Claude	*23	*29	*35	*49	*04	*07							SSP SSO	
3766	Dunn , Paul	*23	*29	*35	*49	*04	*07							SSO	
5214	Eckels/CPMC ,	*23	*29	*35	*49	*04	*07							SSO	
762	Fischer , Gottfried							*23:01	*29:01	*35:02	*49:01	*04:01	*07:01	SSP SSO SBT	A*23:17, C*04:09N /04:30/04:82, C*07:06/07:18/07:343
4079	Fort , Marylise	*23	*29	*35	*49	*04	*07	*23:01	*29:01	*35:02	*49:01	*04:01	*07:01	SSP SSO	A*23:59
3545	Goldstein , Steven							*23:01	*29:01	*35:02	*49:01	*04:01	*07:01	SSP SSO SBT	A*23:17, C*04:30/04:82/07:06 /07:18 /07:343
810	Hamdi , Nuha							*23:01	*29:01	*35:02	*49:01	*04:54	*04:58	SSO	A*23:03/23:04, A*29:02, B*35:129N/35:182, B*49:05/*49:06
8043	Hod , Reut	*23	*29	*35	*49	*04	*07	*23:01	*29:01	*35:02	*49:01	*04:01	*07:01		
771	Israel , Shoshana	*23	*29	*35	*49	*04	*07	*23:01	*29:01	*35:02	*49:01	*04:01:01G	*07:01:01G	SSP SSO	
725	Lardy , N.M.	*23	*29	*35	*49	*04	*07							SSO	
745	Latham , Katy							*23:01	*29:01	*35:02:01	*49:01	*04:01	*07:01	SSP SSO SBT	
278	Lee , Jar-How	*23	*29	*35	*49	*04	*07	*23:01	*29:01	*35:02	*49:01	*04:01	*07:01	SSP SSO	
6649	Lim , Young Ae	*23	*29	*35	*49									SSP	
731	Loewenthal , Ron							*23:01	*29:01	*35:02	*49:01	*04:01	*07:01		
759	Lopez-Cepero , May	*23	*29	*35	*49	*04	*07							SSP	
54	Pancoska , Carol	*23	*29	*35	*49	*04	*07							SSO	
8001	Rao , Prakash	*23	*29	*35	*49	*04	*07							SSP SSO	
3625	Rees , Tracey	*23	*29	*35	*49	*04	*07	*23:01	*29:01	*35:02	*49:01	*04:01	*07:01		A*23:17
1160	Rosen-Bronson , Sa	*23	*29	*35	*49	*04	*07	*23:01	*29:01	*35:02	*49:01			SSO SBT	A*23:17
793	Rubocki , Ronald	*23	*29	*35	*49	*04	*07							SSP	
4251	Schiller , Jennifer	*23	*29	*35	*49	*04	*07	*23:01:01G	*29:01	*35:02	*49:01	*04:01P	*07:01:01G	SSO SBT	
3808	Thornton , Alycia	*23	*29	*35	*49	*04	*07							SSP SBT	
747	Tiercy , Jean-Marie	NT												SSP SSO SBT	
5642	Varnavidou-Nicolaid	*23	*29	*35	*49	*04	*07							SSP	
3186	Watson , Narelle	*23	*29	*35	*49	*04	*07							SSO	

Table 15. Individual laboratory results for Cell #1545-1548 by serology

		Cell No 1545 (Hispanic)										Cell No 1546 (Filipino)							Cell No 1547 (Hispanic)									Cell No 1548 (Caucasian)								
Investigator	Days Old	Viab %	A1	A24	B61	B49	Cw3	Cw7	Bw4	Bw6	OTHERS	Viab %	A24	B38	B51	Cw7	Bw4	OTHERS	Viab %	A2	A68	B61	B51	Cw3	Cw8	Bw4	Bw6	OTHERS	Viab %	A23	A29	B35	B49	Cw4	Cw7	Bw4	Bw6	OTHERS
Askar, Medhat	2	95	+	+	+	+	+	+	+	+		95	+	+	+	+	+		95	+	+	+	B5102	+	+	+	+		95	+	+	+	+	+	+	+	+	
Bengochea, Ca		90	+	+	+	+			+	+		90	+	+	+		+		90	+	+	+	+			+	+		80	+	+	+	+			+	+	
Cecka, J. Mic	2	95	+	+	+	+			+	+		95	+	+	+		+		95	+	+	+	+			+	+		95	+	+	+	+			+	+	
Charron, Domi		98	+	+	B40	+						98	+	+	+				98	+	+	B40	+						95	+	+	+	+					
Claas, F.H.J.	6	90	+	+	+	+	+		+	+		90	+	+	+		+		80	+	A28	+	+	+		+	+		90	+	+	+	+	+		+	+	
Dunn, Paul		95	+	+	+	+			+	+		95	+	+	+		+		95	+	+	+	+			+	+		95	+	+	+	+			+	+	
Enczmann, J		90	+	+	+	+						90	+	+	+				90	+	+	+	B5102						90	+	+	+	+					
Fort, Marylis	6	92	+	+	+	+			+	+		70	+	+	+		+																					
Hahn, Amy B.		100	+	+	+	+	+	+	+	+		100	+	+	+	+	+	Cw6	100	+	+	+	B5102	+		+	+		100	+	+	+	+	+	+	+	+	
Kvam, Vonnett		97	+	+	+	+	+	+	+	+		95	+	+	+	+	+		97	+	A28	+	+	+		+	+		95	+	+	+	+	+	+	+	+	
Latham, Katy	3	80	+	+	+	+			+	+		80	+	+	+		+		80	+	+	+	+			+	+		80	+	+	+	+			+	+	
Loewenthal ,	26	70	+	+	B60	+	+	+				60	+	+	+	+			70	+	+	+	+	+	+				70	+	+	+	+	+	+			
McCoy, Heathe	3	98	+	+	+	+	w10	+	+	+		98	+	+	+	+	+		98	+	+	+	+	w10	+	+	+		98	+	+	+	+	+	+	+	+	
Pancoska, Car	3	97	+	+	+	+	w10	+	+	+		97	+	+	+	+	+	Cw6	98	+	+	+	B5102	w10		+	+		98	+	+	+	+	+	+	+	+	
Permpikul, Ve	6	85	+	+	+	+			+	+		85	+	+	+		+		85	+	+	+	+			+	+		85	+	+	+	+			+	+	
Pule, Ziningi		75	+	A80	+	+	w4	+				75	A23	+	+	+		Cw6>	75	A33		B40	B53	+	+				75	+	+	+	+	+	+			
Rees, Tracey	3	90	+	+	+	+	+	+	+	+		90	+	+	+	+	+		90	+	A28	+	+	+	+	+	+		90	+	+	+	+	+	+	+	+	
Renac, Virgin	6	99	+	+	B40	B21			+	+		99	+	+	+		+		99	+	A28	B40	+			+	+		99	+	+	+	B21			+	+	
Rosen-Bronson		95	+	+	+	+	+	+	+	+		90	+	+	+	+	+		95	+	+	+	+	w10	+	+	+		95	+	+	+	+	+	+	+	+	
Rubocki, Rona		98	+	+	B40	+	+	+	+	+		98	+	+	+	+	+		98	+	A28	B40	+	+		+	+		98	+	+	+	+	+	+	+	+	
Shai, Isaac	8	88	+	+	B40	B21	+	+	+	+	B48>	91	+	+	B5	+	+	Cw6>	88	+	A28	B40	+	+	+	+	+	B35	82	+	+	+	B21	+	+	+	+	B52>
Thornton, Aly		90	+	+	+	+	+	+	+	+		90	+	+	+	+	+		90	+	+	+	+	+	+	+	+		90	+	+	+	+	+	+	+	+	
Tiercy, Jean-	6	85	+	+	+	+			+	+		85	+	+	+		+																					
Varnavidou-Ni		98	+	+	B4005	+			+	+		98	+	+	+		+		98	+	+	B40	+			+	+		98	+	+	+	+			+	+	
Vidan-Jeras,	7	90	+	+	+	+	+	+	+	+		90	+	+	+	+	+		95	+	+	B60	+	+		+	+		95	+	+	+	+	+	+	+	+	

Serum Exchange #545

The results for Serum Exchange 545 (**sera 1173 -1176**), are summarized in Tables 16-21 and individual laboratory results by method are listed in Tables 22-32. Sera strongly positive to A29, A9 (A23, A29) and 5C specificities were examined in this study.

Sample 1173 was reported to be strongly positive to A29 by all methods. Additional strong reactivity to B12 (B44 and B45) was detected by Antiglobulin, Luminex, Elisa, and C1q. Antiglobulin, Luminex, and Elisa also reported strong reactivity to A31, A34, and B18. Anti-A2 and –B37 reactivity, along with reactivity to a number of 7C, 8C, and 12C specificities, was also reported by Luminex and Elisa. In addition, Luminex reported strong C -locus reactivity to Cw7, Cw15, and Cw17.

1173	method	#labs	A29	B45	B44	B12	B18	A25	A30	A31	A32	A34	A2	A33	A68	A69	A74	B54	B41	B42	B55	B59	B37
	NIH-Std	4	100			25		25	25		25												
	NIH-Ext	3	100																				
	AHG	2	100	100	100		100			100		100											
	Luminex	24	100	100	100		88	100	96	100	100	100	100	100	100	100	100	100	96	96	96	96	96
	Flow	1	no specificities assigned																				
	ELISA	2	100	100	100		100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100
	C1q	1	100	100	100																		
	Other	3	67	67																			
1173	method	#labs	A26	A66	B8	B38	B39	B67	A3	A1	A23	A36	A80	Cw7	Cw17	Cw15	A43	B73	B76	B82	B56	B7	B65
	NIH-Std	4																					
	NIH-Ext	3																					
	AHG	2																					
	Luminex	24	92	79	100	92	88	92	92	83	75	92	83	100	100	79	96	100	92	92	88		
	Flow	1																					
	ELISA	2	100	100	100	100	100	100	100	100	100	50	50									100	100
	C1q	1																					
	Other	3																					

Class II reactivity to anti-DR17 and –DR18 antisera was reported by NIH-extended, Luminex, C1q, and Luminex PRA. Reactivity to DR13, DR14, and DQ2 was also detected by Luminex, C1q, and Luminex PRA. Luminex, along with Luminex PRA, reported additional reactivity to DR11, DR12, DR7, DR8, DR9, and DQ3. Reactivity to a number of DP and DQ specificities was also reported by Luminex.

1173	method	#labs	DR17	DR18	DR3	DR13	DR14	DQ2	DR11	DR12	DR7	DR8	DR9	DQ7	DR52	DR15	DPw4	DPw2	DR16	DR51	DR10	DP18	DQ5	DQ6	DQ8	DQ9	DQ4	DPw1	DPw5	DP402	DPw6	DR53	
	NIH-Std	1			100																												
	NIH-Ext	1	100	100																													
	Luminex		95	95		100	100	100	100	100	100	100	100	79	100	95	79	74	68	63	58	53	53	42	42	42	42	26	26	16	16	16	
	Flow	1	no specificities assigned																														
	C1q	1	100	100		100	100	100																									
	Other	2	50	50		50	50	50	50	50	50	50	50	50																			

For **sample 1174**, strong anti-A29 reactivity was reported by all methods. Additional reactivity to A1, A36, B41, and a number of 2C, 5C, 7C, and 10C specificities was detected by various methods.

Strong reactivity to a number of DR specificities (DR8, DR11, DR12, DR13, DR14, DR17, DR18) was reported by Luminex and Luminex PRA. Additional reactivity to other DR specificities, as well as reactivity to DQ2 and DQ5, was also detected by Luminex.

1174	method	#labs	A29	A1	A36	B35	B50	B53	B42	A31	B7	B71	B75	B62	B49	B51	B56	B55	A30	A33	A23	A2	A26	A69	A68	B63	B72
	NIH-Std	4	100	25	25					25											25						
	NIH-Ext	3	100			33	67					33	33	33						33							
	AHG	3	67	100	100	100	33	33	33	67	33	33			67	33	33	33	67			33	33	33	33		
	Luminex	24	100	96	96	100	96	100	96	79	83	92	100	92	96	83	100	100	92	79	75		92	75		100	92
	Flow	1	no specificities assigned																								
	ELISA	2	100	100	100	100	100	100	100	100	50	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100
	C1q	1	100	100	100																						
	Other	3	33	33		33		33	33		33											33					
1174	method	#labs	B67	B54	B59	B78	B58	B46	B13	A80	A74	A34	B41	B57	B77	B82	A2	A43	A66	B37	Cw4	A32	B27	B39	B44		
	NIH-Std	4							25													25					
	NIH-Ext	3																									
	AHG	3																					33	33	33		
	Luminex	24	92	88	83	79	79	79		92	83	79	75	79	92	75	88	92			75						
	Flow	1																									
	ELISA	2	50	50	50	50	50	50	100	100	100	100	100	50					100	100							
	C1q	1																									
	Other	3																									

1174	method	#labs	DR11	DR12	DR13	DR14	DR17	DR18	DR8	DR10	DR9	DR53	DR52	DR7	DQ2	DQ5
	NIH-Std	1	NT													
	NIH-Ext	1	no specificities assigned													
	Luminex	19	100	100	100	100	95	95	100	100	100	100	84	58	42	16
	Flow	1	no specificities assigned													
	C1q	1	NT													
	Other	2	50	50	50	50	50	50	50							

1175	method	#labs	A23	A24	A32	A25	B57	B58	B17	B49	B21	B51	B52	B5	A2	A68	A69	A1	A29	B53	B63	B38	B59	B13	B37	B44	B45	B49
	NIH-Std	4	75	100	25	25	25		25		25	25	25	25														
	NIH-Ext	3	100	100	33		33	33		33					33													
	AHG	2	100	100	100	50	100		50	50		100	50			50	50		50									
	Luminex	22	100	100	95	100	95	100		100		100	95		100	100	100	91	59	100	100	100	86	100	100	100	64	100
	Flow	1	no specificities assigned																									
	ELISA	2	100	100	100	100	100	100		100		100	100		100	100	100	100	100	100	100	100	100	100	100	100	100	100
	C1q	1	100	100	100	100	100	100		100		100	100							100	100	100	100					
	Other	2	50	50	50	50									50	50		50										

1175	method	#labs	B27	B47	A80	A74	B54	B53	B77	B76	Cw2	Cw4	Cw15	Cw18	Cw5	Cw17	A43	Cw6	Cw7	Cw14	A34	A11	A3	A31	A33	A26	B35	Bw4
	NIH-Std	4																								25		
	NIH-Ext	3																										33
	AHG	2				50		100																			50	
	Luminex	22	95	95	86		59		100	86	82	82	77	73	68	59	55	50	50	45	68							
	Flow	1																										
	ELISA	2	100	100	100	100	100	100														100	100	100	100			
	C1q	1																										
	Other	2																										

Sample 1175 was found to be positive to A23, A24, and A32 by all methods. In addition, reactivity to a number of 5C specificities was reported by various methods. Luminex and Elisa also reported strong reactivity to 7C and 12C specificities. Reactivity to a number of C-locus specificities was reported by Luminex.

Anti-DR10 and -DR4 reactivity was detected by Luminex and Luminex PRA. Additional reactivity to other DR and DQ specificities was also reported by Luminex.

1175	method	#labs	DR10	DR4	DR53	DR9	DQ9	DQ8	DQ7	DR1	DR7	DR103	DR15	DR16	DR51	DQ2	DQ5	DR52	DQ6
	NIH-Std	1	NT																
	NIH-Ext	1	no specificities assigned																
	Luminex	17	94	100	94	88	76	71	71	59	59	53	53	47	47	41	35	29	24
	Flow	1	no specificities assigned																
	C1q	1	NT																
	Other	2	50	50															

1176	method	#labs	DR13	DR17	DR18	DR52	DR14	DQ2	DR11	DP11
	NIH-Std	1	NT							
	NIH-Ext	1	no specificities assigned							
	Luminex	18	67	94	94	78	67	28	22	17
	Flow	1	no specificities assigned							
	C1q	1	NT							
	Other	2	50	50	50					

For **sample 1176**, strong reactivity to 5C specificities was reported by all methods. Additional reactivity to 12C (B37, B44, B45) and 7C specificities was detected by various methods. Some reactivity to 8C specificities was also reported by various methods.

Anti-DR13, -DR17, and –DR18 reactivity was reported by Luminex and Luminex PRA. Additional class II reactivity to DR52, DR11, DR14, DQ1, and DP11 was reported by Luminex.

1176	method	#labs	B50	B49	B21	B35	B51	B53	B72	B62	B44	B45	B71	B13	B60	B61	B75	B37	B18	B38	B41	B47	B56	B63	B78	B52	A23	A24	A29
	NIH-Std	4	75	50	50	50	75	50						50												50	50	50	
	NIH-Ext	3	100	100		67			100	100	100	100	100	33	67		100	33	33	33	33	33							
	AHG	2	100	100		100	100	100	50	50	100	100	50	50	50	50							50	50					
	Luminex	23	100	96		96	96	100	100	96	100	96	96	100	96	100	100	100	96	87	96	100	100	96	83	96	78	87	17
	Flow	1	no specificities assigned																										
	ELISA	2	100	100		100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100		50
	C1q	1	100	100			100	100	100																				
	Other	3	67	67		67	67	67	67	67	33				67	67									33				

1176	method	#labs	B53	B57	B58	B55	B59	B48	B54	B46	B76	B77	B67	B64	B39	B8	Cw10	A32	A11	A25	A26	A68	A3	B7	B27	B70
	NIH-Std	4	50																50	50	50	50		50		
	NIH-Ext	3																								
	AHG	2																					50		50	50
	Luminex	23	100	100	96	91	91	83	87	91	91	91	83	83	78	65	65									
	Flow	1																								
	ELISA	2		100	100	100	100	100										50								
	C1q	1																								
	Other	3																								

Table 16. Summary of the 545th Serum Exchange (Serum #1173-1176) by NIH-Standard and NIH-Extended - class I

Method: NIH-Standard

*** Serum 1173 ***		
4 typing Labs		
Antigen	Consensus	Inclusion
A29	100%	58%
A30	25%	100%
A32	25%	100%
B12	25%	100%
A25	25%	50%

*** Serum 1174 ***		
4 typing Labs		
Antigen	Consensus	Inclusion
A29	100%	50%
A1	25%	100%
A31	25%	100%
A36	25%	100%
B13	25%	100%
A23	25%	67%
A32	25%	50%

*** Serum 1175 ***		
4 typing Labs		
Antigen	Consensus	Inclusion
A24	100%	100%
A23	75%	100%
A25	25%	100%
A26	25%	100%
B17	25%	100%
B21	25%	100%
B5	25%	100%
B51	25%	100%
B52	25%	100%
B57	25%	100%
A32	25%	88%

*** Serum 1176 ***		
4 typing Labs		
Antigen	Consensus	Inclusion
B50	75%	100%
B51	75%	25%
A23	50%	100%
B49	50%	100%
B35	50%	40%
A11	25%	100%
A25	25%	100%
A26	25%	100%
A68	25%	100%
B13	25%	100%
B21	25%	100%
B53	25%	100%
B7	25%	80%
A24	25%	75%
B52	25%	50%

Method: NIH-Extended

*** Serum 1173 ***		
3 typing Labs		
Antigen	Consensus	Inclusion
A29	100%	100%

*** Serum 1174 ***		
3 typing Labs		
Antigen	Consensus	Inclusion
A29	100%	50%
B50	67%	50%
B35	33%	100%
B62	33%	100%
B71	33%	100%
B75	33%	100%
A33	33%	50%

*** Serum 1175 ***		
3 typing Labs		
Antigen	Consensus	Inclusion
A23	100%	100%
A24	100%	100%
A2	33%	100%
A32	33%	100%
B49	33%	100%
B57	33%	100%
B58	33%	100%
BW4	33%	78%

*** Serum 1176 ***		
3 typing Labs		
Antigen	Consensus	Inclusion
B45	100%	100%
B49	100%	100%
B50	100%	100%
B62	100%	100%
B71	100%	100%
B72	100%	100%
B75	100%	100%
B44	100%	75%
B35	67%	100%
B60	67%	80%
B13	33%	100%
B18	33%	100%
B37	33%	100%
B38	33%	100%
B41	33%	100%
B47	33%	100%

Table 17. Summary of the 545th Serum Exchange (Serum #1173-1176) by Antiglobulin and Other - class I

Method: Antiglobulin

*** Serum 1173 ***		
2 typing Labs		
Antigen	Consensus	Inclusion
A29	100%	100%
B44	100%	100%
B45	100%	100%
A31	50%	100%
A34	50%	100%
B18	50%	100%

*** Serum 1174 ***		
3 typing Labs		
Antigen	Consensus	Inclusion
A1	100%	100%
A36	100%	100%
B35	100%	100%
A29	67%	100%
B49	67%	100%
A31	67%	80%
A30	67%	78%
A2	33%	100%
A68	33%	100%
A69	33%	100%
B27	33%	100%
B39	33%	100%
B42	33%	100%
B44	33%	100%
B50	33%	100%
B51	33%	100%
B53	33%	100%
B56	33%	100%

*** Serum 1175 ***		
2 typing Labs		
Antigen	Consensus	Inclusion
A23	100%	100%
A24	100%	100%
A32	100%	100%
B51	100%	100%
B53	100%	100%
B57	100%	100%
A25	50%	100%
A29	50%	100%
A68	50%	100%
A69	50%	100%
A74	50%	100%
B17	50%	100%
B35	50%	100%
B49	50%	100%
B52	50%	100%

*** Serum 1176 ***		
2 typing Labs		
Antigen	Consensus	Inclusion
B35	100%	100%
B44	100%	100%
B45	100%	100%
B49	100%	100%
B50	100%	100%
B51	100%	100%
B53	100%	100%
A3	50%	100%
B13	50%	100%
B27	50%	100%
B56	50%	100%
B60	50%	100%
B61	50%	100%
B62	50%	100%
B63	50%	100%
B70	50%	100%
B71	50%	100%
B72	50%	100%

Method: Other

*** Serum 1173 ***		
3 typing Labs		
Antigen	Consensus	Inclusion
A29	67%	100%
B45	67%	100%

*** Serum 1174 ***		
3 typing Labs		
Antigen	Consensus	Inclusion
A1	33%	100%
A2	33%	100%
A29	33%	100%
B35	33%	100%
B42	33%	100%
B53	33%	100%
B7	33%	100%

*** Serum 1175 ***		
2 typing Labs		
Antigen	Consensus	Inclusion
A1	50%	100%
A2	50%	100%
A23	50%	100%
A24	50%	100%
A25	50%	100%
A32	50%	100%
A68	50%	100%

*** Serum 1176 ***		
3 typing Labs		
Antigen	Consensus	Inclusion
B35	67%	100%
B49	67%	100%
B50	67%	100%
B51	67%	100%
B53	67%	100%
B60	67%	100%
B61	67%	100%
B62	67%	100%
B72	67%	100%
B78	33%	100%
B44	33%	100%

Table 18. Summary of the 545th Serum Exchange (Serum #1173-1176) by Luminex - class I

*** Serum 1173 ***		
24 typing Labs		
Antigen	Consensus	Inclusion
A25	100%	100%
A29	100%	100%
A31	100%	100%
A32	100%	100%
A33	100%	100%
A34	100%	100%
A68	100%	100%
A69	100%	100%
A74	100%	100%
B44	100%	100%
B45	100%	100%
B54	100%	100%
B73	100%	100%
B8	100%	100%
CW17	100%	100%
CW7	100%	100%
A2	100%	86%
A43	96%	100%
B37	96%	100%
B41	96%	100%
B42	96%	100%
B55	96%	100%
A30	96%	90%
B59	96%	75%
A26	92%	100%
A36	92%	100%
B38	92%	100%
B67	92%	100%
B76	92%	100%
B82	92%	100%
A3	92%	78%
B18	88%	100%
B39	88%	100%
B56	88%	80%
A80	83%	100%
A1	83%	83%
A66	79%	100%
CW15	79%	100%
A23	75%	100%

*** Serum 1174 ***		
24 typing Labs		
Antigen	Consensus	Inclusion
A29	100%	100%
B35	100%	100%
B53	100%	100%
B55	100%	100%
B56	100%	100%
B75	100%	100%
B63	100%	80%
A1	96%	100%
A36	96%	100%
B42	96%	100%
B49	96%	100%
B50	96%	100%
A26	92%	100%
A30	92%	100%
A43	92%	100%
B62	92%	100%
B67	92%	100%
B71	92%	100%
B72	92%	100%
B77	92%	100%
A80	92%	67%
B54	88%	75%
A2	88%	62%
A74	83%	100%
B7	83%	83%
B51	83%	57%
B59	83%	50%
A33	79%	100%
A34	79%	100%
B57	79%	100%
B78	79%	100%
A31	79%	75%
B58	79%	75%
B46	79%	67%
A23	75%	100%
A69	75%	100%
B82	75%	100%
CW4	75%	100%
B41	75%	75%

*** Serum 1175 ***		
22 typing Labs		
Antigen	Consensus	Inclusion
A23	100%	100%
A24	100%	100%
A25	100%	100%
A68	100%	100%
B13	100%	100%
B37	100%	100%
B38	100%	100%
B44	100%	100%
B49	100%	100%
B51	100%	100%
B53	100%	100%
B58	100%	100%
B63	100%	100%
B77	100%	100%
A2	100%	95%
A69	100%	33%
A32	95%	100%
B47	95%	100%
B52	95%	100%
B57	95%	100%
B27	95%	80%
A1	91%	73%
A80	86%	100%
B59	86%	100%
B76	86%	100%
CW2	82%	100%
CW4	82%	75%
CW15	77%	100%
CW18	73%	100%
CW5	68%	100%
A34	68%	50%
B45	64%	100%
B54	59%	100%
CW17	59%	100%
A29	59%	50%
A43	55%	100%
CW6	50%	100%
CW7	50%	100%
CW14	45%	100%

*** Serum 1176 ***		
23 typing Labs		
Antigen	Consensus	Inclusion
B13	100%	100%
B37	100%	100%
B44	100%	100%
B47	100%	100%
B50	100%	100%
B53	100%	100%
B56	100%	100%
B57	100%	100%
B61	100%	100%
B72	100%	100%
B75	100%	100%
B18	96%	100%
B35	96%	100%
B41	96%	100%
B45	96%	100%
B49	96%	100%
B51	96%	100%
B52	96%	100%
B58	96%	100%
B60	96%	100%
B62	96%	100%
B63	96%	100%
B71	96%	100%
B46	91%	100%
B55	91%	100%
B59	91%	100%
B76	91%	100%
B77	91%	100%
B38	87%	100%
B54	87%	100%
A24	87%	92%
B48	83%	100%
B64	83%	100%
B67	83%	100%
B78	83%	100%
A23	78%	100%
B39	78%	100%
B8	65%	100%
CW10	65%	100%

Table 19. Summary of the 545th Serum Exchange (Serum #1173-1176) by ELISA- class I

*** Serum 1173 ***		
2 typing Labs		
Antigen	Consensus	Inclusion
A2	100%	100%
A25	100%	100%
A26	100%	100%
A29	100%	100%
A3	100%	100%
A30	100%	100%
A31	100%	100%
A32	100%	100%
A33	100%	100%
A34	100%	100%
A66	100%	100%
A68	100%	100%
A69	100%	100%
A74	100%	100%
B18	100%	100%
B37	100%	100%
B38	100%	100%
B39	100%	100%
B41	100%	100%
B42	100%	100%
B44	100%	100%
B45	100%	100%
B54	100%	100%
B55	100%	100%
B59	100%	100%
B65	100%	100%
B67	100%	100%
B7	100%	100%
B8	100%	100%
A23	100%	50%
A1	50%	100%

*** Serum 1174 ***		
2 typing Labs		
Antigen	Consensus	Inclusion
A1	100%	100%
A2	100%	100%
A26	100%	100%
A29	100%	100%
A36	100%	100%
A68	100%	100%
A69	100%	100%
A80	100%	100%
B13	100%	100%
B35	100%	100%
B41	100%	100%
B42	100%	100%
B49	100%	100%
B50	100%	100%
B53	100%	100%
B55	100%	100%
B56	100%	100%
B62	100%	100%
B63	100%	100%
B71	100%	100%
B72	100%	100%
B75	100%	100%
A23	100%	50%
B51	100%	50%
A30	50%	100%
A31	50%	100%
A33	50%	100%
A34	50%	100%
A66	50%	100%
A74	50%	100%
B37	50%	100%

*** Serum 1175 ***		
2 typing Labs		
Antigen	Consensus	Inclusion
A1	100%	100%
A11	100%	100%
A2	100%	100%
A23	100%	100%
A24	100%	100%
A25	100%	100%
A29	100%	100%
A3	100%	100%
A31	100%	100%
A32	100%	100%
A33	100%	100%
A68	100%	100%
A69	100%	100%
A74	100%	100%
A80	100%	100%
B13	100%	100%
B27	100%	100%
B37	100%	100%
B38	100%	100%
B44	100%	100%
B45	100%	100%
B47	100%	100%
B49	100%	100%
B51	100%	100%
B52	100%	100%
B53	100%	100%
B54	100%	100%
B57	100%	100%
B58	100%	100%
B59	100%	100%
B63	100%	100%

*** Serum 1176 ***		
2 typing Labs		
Antigen	Consensus	Inclusion
A23	100%	100%
B13	100%	100%
B18	100%	100%
B35	100%	100%
B37	100%	100%
B38	100%	100%
B41	100%	100%
B44	100%	100%
B45	100%	100%
B47	100%	100%
B48	100%	100%
B49	100%	100%
B50	100%	100%
B51	100%	100%
B52	100%	100%
B53	100%	100%
B55	100%	100%
B56	100%	100%
B57	100%	100%
B58	100%	100%
B59	100%	100%
B60	100%	100%
B61	100%	100%
B62	100%	100%
B63	100%	100%
B71	100%	100%
B72	100%	100%
B75	100%	100%
B78	100%	100%
A29	50%	100%
A32	50%	100%

Table 20. Summary of the 545th Serum Exchange (Serum #1173-1176) by NIH, C1q, Flow Cytometry, and Other - class II

Method: NIH-Standard and NIH-Extended

*** Serum 1173 ***		
2 typing Labs		
Antigen	Consensus	Inclusion
DR3	50%	100%
DR17	50%	100%
DR18	50%	100%

*** Serum 1174 ***		
2 typing Labs		
Antigen	Consensus	Inclusion
no consensus		

*** Serum 1175 ***		
2 typing Labs		
Antigen	Consensus	Inclusion
no consensus		

*** Serum 1176 ***		
2 typing Labs		
Antigen	Consensus	Inclusion
no consensus		

Method: C1q and Flow Cytometry

*** Serum 1173 ***		
2 typing Labs		
Antigen	Consensus	Inclusion
DQ2	50%	100%
DR13	50%	100%
DR14	50%	100%
DR17	50%	100%
DR18	50%	100%

*** Serum 1174 ***		
2 typing Labs		
Antigen	Consensus	Inclusion
no consensus		

*** Serum 1175 ***		
2 typing Labs		
Antigen	Consensus	Inclusion
no consensus		

*** Serum 1176 ***		
2 typing Labs		
Antigen	Consensus	Inclusion
no consensus		

Method: Other

*** Serum 1173 ***		
2 typing Labs		
Antigen	Consensus	Inclusion
DQ2	50%	100%
DQ7	50%	100%
DR11	50%	100%
DR12	50%	100%
DR13	50%	100%
DR14	50%	100%
DR17	50%	100%
DR18	50%	100%
DR7	50%	100%
DR8	50%	100%
DR9	50%	100%

*** Serum 1174 ***		
2 typing Labs		
Antigen	Consensus	Inclusion
DR11	50%	100%
DR12	50%	100%
DR13	50%	100%
DR14	50%	100%
DR17	50%	100%
DR18	50%	100%
DR8	50%	100%

*** Serum 1175 ***		
2 typing Labs		
Antigen	Consensus	Inclusion
DR10	50%	100%
DR4	50%	100%

*** Serum 1176 ***		
2 typing Labs		
Antigen	Consensus	Inclusion
DR13	50%	100%
DR17	50%	100%
DR18	50%	100%

Table 21. Summary of the 545th Serum Exchange (Serum #1173-1176) by Luminex - class II

*** Serum 1173 ***		
19 typing Labs		
Antigen	Consensus	Inclusion
DQ2	100%	100%
DR11	100%	100%
DR12	100%	100%
DR13	100%	100%
DR14	100%	100%
DR52	100%	100%
DR7	100%	100%
DR8	100%	100%
DR9	100%	100%
DR15	95%	100%
DR17	95%	100%
DR18	95%	100%
DPW4	79%	100%
DQ7	79%	82%
DPW2	74%	100%
DR16	68%	100%
DR51	63%	100%
DR10	58%	100%
DP18	53%	100%
DQ5	53%	100%
DQ6	42%	100%
DQ8	42%	100%
DQ9	42%	100%
DQ4	42%	100%
DPW1	26%	100%
DPW5	26%	100%
DP402	16%	100%
DPW6	16%	100%
DR53	16%	100%

*** Serum 1174 ***		
19 typing Labs		
Antigen	Consensus	Inclusion
DR10	100%	100%
DR11	100%	100%
DR12	100%	100%
DR13	100%	100%
DR14	100%	100%
DR8	100%	100%
DR9	100%	100%
DR53	100%	94%
DR17	95%	100%
DR18	95%	100%
DR52	84%	97%
DR7	58%	100%
DQ2	42%	40%
DQ5	16%	100%

*** Serum 1175 ***		
17 typing Labs		
Antigen	Consensus	Inclusion
DR4	100%	100%
DR10	94%	67%
DR53	94%	41%
DR9	88%	43%
DQ9	76%	40%
DQ8	71%	100%
DQ7	71%	53%
DR1	59%	100%
DR7	59%	100%
DR103	53%	100%
DR15	53%	100%
DR16	47%	100%
DR51	47%	100%
DQ2	41%	40%
DQ5	35%	50%
DR52	29%	33%
DQ6	24%	33%

*** Serum 1176 ***		
18 typing Labs		
Antigen	Consensus	Inclusion
DR17	94%	100%
DR18	94%	100%
DR52	78%	100%
DR14	67%	88%
DR13	67%	56%
DQ2	28%	40%
DR11	22%	100%
DP11	17%	100%

Table 22. Individual laboratory results for Serum #1173-#1176 by NIH-Standard and NIH-Extended

	**** Serum 1173 ****			**** Serum 1174 ****				**** Serum 1175 ****				**** Serum 1176 ****											
Investigator	% POS	A29	Other	% POS	A29		Other	% POS	A24	A23	Other	% POS	B50	B51	A23	B49	B35						Other	Method
Claas, F.H.J.	35	+	A25,A30,A32	13	+		B13,A31,A32	35	+	+	A25,A26,A32	54	+		+	+							A11,A24,B13,B7 >	STD
Thornton, Alycia		+			+				+					+										STD
Vasilescu, Rodica	20	+	B12	18	+		A1,A36	40	+	+	B21,B5,B17 >	44	+	+		+	+						B21,B53	STD
Watson, Narelle	1	+		10	+		A23	26	+	+	B51,B52	22	+	+	+		+						B52	STD

	**** Serum 1173 ****			**** Serum 1174 ****				**** Serum 1175 ****				**** Serum 1176 ****											
Investigator	% POS	A29	Other	% POS	A29	B50	Other	% POS	A23	A24	Other	% POS	B45	B49	B50	B62	B71	B72	B75	B44	B35	B60	Other	Method
Dunn, Paul	11	+		26	+	+	B62,B75,B35,B71	60	+	+	A2,A32	75	+	+	+	+	+	+	+	+	+	+	B61,B48,B13,B47 >	EXT
Lardy, N.M.	8	+		9	+	+	A33	74	+	+	BW4	62	+	+	+	+	+	+	+	+	+	+		EXT
Reed, Elaine F. PhD	7	+		13	+			58	+	+	B49,B57,B58	63	+	+	+	+	+	+	+	+			B63	EXT

Table 23. Individual laboratory results for Serum #1173-#1176 by Antiglobulin and Other

	**** Serum 1173 ****					**** Serum 1174 ****									**** Serum 1175 ****									**** Serum 1176 ****											
Investigator	% POS	A29	B44	B45	Other	% POS	A1	A36	B35	A29	B49	A31	A30	Other	% POS	A23	A24	A32	B51	B53	B57		Other	% POS	B35	B44	B45	B49	B50	B51	B53			Other	Method
Cecka, J. Michael P	NT					65	+	+	+	+	+	+	+	B50,B7>	NT									NT											AHG
Hahn, Amy B. PhD		+	+	+	A34,A31>		+	+	+	+	+	+	+	A2,B44>		+	+	+	+	+	+		A29,A74>		+	+	+	+	+	+	+			B60,B61>	AHG
Vasilescu, Rodica	35	+	+	+		30	+	+	+						40	+	+	+	+	+	+		B49,B52>	50	+	+	+	+	+	+	+			B70	AHG

	**** Serum 1173 ****					**** Serum 1174 ****									**** Serum 1175 ****									**** Serum 1176 ****											
Investigator	% POS	A29	B45	B76	Other	% POS	A1	A2	A29	B35	B42	B53	B7	Other	% POS	A1	A2	A23	A24	A25	A32	A68	Other	% POS	B35	B49	B50	B51	B60	B61	B62	B72	B53	Other	Method
Hamdi, Nuha	NT					89		+							NT									NT											Other
Phelan, Donna L.	100					91									93									98											Other
Reed, Elaine F. PhD	98	+	+			82	+		+	+	+	+	+		86	+	+	+	+	+	+	+		92	+	+	+	+	+	+	+	+	+		Other
Hod, Reut		+	+	+	A43,B44>	NT									NT										+	+	+	+	+	+	+	+	+	B78,B44>	Other

Table 24. Individual laboratory results for Serum #1173 Luminex

	**** Serum 1173 ****																																									
Investigator	% POS	A25	A29	A31	A32	A33	A34	A68	A69	A74	B44	B45	B54	B73	B8	CW17	CW7	A2	A43	B37	B41	B42	B55	A30	B59	A26	A36	B38	B67	B76	B82	A3	B18	B39	B56	A80	Other	Method
Arnold, Paula PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A203,A66,A1,CW15 >	LMX
Bengochea, Carrett	40	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+				+	+		+				A203,A6601,A6602,B3901	LMX
Cecka, J. Michael P	84	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B61,A66,B49 >	LMX
Chen, Dong-Feng P		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	CW4,CW6,A24,A203 >	LMX
Dunn, Paul		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,A203,B60,B61 >	LMX
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,A24,B60,B61 >	LMX
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B60,B61,B48 >	LMX
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,A24,B60,B61 >	LMX
Hamdi, Nuha	98	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,A24,B60,B61 >	LMX
Hod, Reut	100	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+		+	+	+		+	+	+	+	+		A23,A6601,A6602	LMX
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW6,A11,A24,B60 >	LMX
Lardy, N.M.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+						+	+				+	+						A66	LMX
Libyh/Roulin, Tabary	95	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+		+	+	A203,B60,B61,B49 >	LMX
Martinho, Paiva &		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+		+	+		+	+	+	A11,A66,B13,B27 >	LMX
McCoy, Heather	58	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B61,A66,B49 >	LMX
Pancoska, Carol Ph	80	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,A24,B60,B61 >	LMX
Permpikul, Vejbaesy	52	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,A66,B50,A1 >	LMX
Phelan, Donna L.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B60,B61,A66 >	LMX
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,A24,B60,B61 >	LMX
Rosen-Bronson, Sa	100	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,A24,B60,B61 >	LMX
Terasaki, Paul I. Ph		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,A24,B60,B61 >	LMX
Thornton, Alycia		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+			A66	LMX
Vasilescu, Rodica		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A24,B60 >	LMX
Vather, Kuben		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A11,A24 >	LMX

Table 25. Individual laboratory results for Serum #1174 Luminex

	**** Serum 1174 ****																																				
Investigator	% POS	A29	B35	B53	B55	B56	B75	B63	A1	A36	B42	B49	B50	A26	A30	A43	B62	B67	B71	B72	B77	A80	B54	A2	A74	B7	B51	B59	A33	A34	B57	B78	A31	B58	B46	A23	Other	Method
Arnold, Paula PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				+										LMX
Bengochea, Carrett	15	+	+	+	+	+	+	+			+			+		+	+								+											B82	LMX
Cecka, J. Michael P	73	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		B52,B82,A68,A69 >	LMX
Chen, Dong-Feng P		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	CW4,A24,A203,B13 >	LMX
Dunn, Paul		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A24,A203,A66 >	LMX
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A24,A66,B13,B52 >	LMX
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A24,A66,B13 >	LMX
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A24,A66,B13 >	LMX
Hamdi, Nuha	89	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A24,A66,B13 >	LMX
Hod, Reut	84	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+		+	+		+		+	+	+		+	+	+	CW4,A11,B13,B82 >	LMX
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A11,A24,B60 >	LMX
Lardy, N.M.		+	+	+	+	+	+	+	+	+		+	+															+									LMX
Libyh/Roulin, Tabary	82	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	CW4,A24,B13,B52 >	LMX
Martinho, Paiva &		+	+	+	+	+	+	+	+	+	+	+	+		+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,B13,B27,B52 >	LMX
McCoy, Heather	53	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	CW4,A24,A66,B52 >	LMX
Pancoska, Carol Ph	64	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A24,A66,B13 >	LMX
Permpikul, Vejbaesy	33	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+		+			+	+				B82	LMX
Phelan, Donna L.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A66,B13,B52 >	LMX
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A24,A66,B13 >	LMX
Rosen-Bronson, Sa	95	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A24,A66,B13 >	LMX
Terasaki, Paul I. Ph		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A24,A66,B82 >	LMX
Thornton, Alycia		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+								+			+		CW4,A68,A69,CW1 >	LMX
Vasilescu, Rodica		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A24,B13,B27 >	LMX
Vather, Kuben		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A24,B60,A66 >	LMX

Table 26. Individual laboratory results for Serum #1175 Luminex

	**** Serum 1175 ****																																				
Investigator	% POS	A23	A24	A25	A68	B13	B37	B38	B44	B49	B51	B53	B58	B63	B77	A2	A69	A32	B47	B52	B57	B27	A1	A80	B59	B76	CW2	CW4	CW15	CW18	CW5	A34	B45	B54	CW17	A29	Other	Method
Arnold, Paula PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+								A203,A2403	LMX
Bengochea, Carrett	32	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				+				+							BW4,A2403	LMX
Cecka, J. Michael P	78	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+										LMX
Chen, Dong-Feng P		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	CW6,A203,A43,CW10 >	LMX
Dunn, Paul		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW6,A11,A203,A66 >	LMX
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	B82,BW4,B2708,A6602	LMX
Fort, Marylise	NT																																					LMX
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	CW6,B61,A66,B78 >	LMX
Hamdi, Nuha	82	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW6,A11,B61,A66 >	LMX
Hod, Reut	86	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+		+	+	+	+	+				B60,B61,B48,B82 >	LMX
Holdsworth, Rhonda	?																																					LMX
Lardy, N.M.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+																LMX
Libyh/Roulin, Tabary	85	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW6,A203,B82,B55 >	LMX
Martinho, Paiva &		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+		+		+		+	+	+	+	+	+	+	+	+	+	CW6,B7,A30,A33 >	LMX
McCoy, Heather	37	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+									CW7	LMX
Pancoska, Carol Ph	53	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	A66,A43	LMX
Permpikul, Vejbaesy	38	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+			+						LMX
Phelan, Donna L.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW6,A66,A43,CW7	LMX
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	A66,A26,A33,A43	LMX
Rosen-Bronson, Sa	97	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW6,A66,A43,BW4 >	LMX
Terasaki, Paul I. Ph		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW6,A11,B61,A66 >	LMX
Thornton, Alycia		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+			+	+								LMX
Vasilescu, Rodica		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		CW6,A43,CW1,CW10 >	LMX
Vather, Kuben		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW6,A66,B82,A26 >	LMX

Table 27. Individual laboratory results for Serum #1176 Luminex

	**** Serum 1176 ****																																						
Investigator	% POS	B13	B37	B44	B47	B50	B53	B56	B57	B61	B72	B75	B18	B35	B41	B45	B49	B51	B52	B58	B60	B62	B63	B71	B46	B55	B59	B76	B77	B38	B54	A24	B48	B64	B67	B78	Other	Method
Arnold, Paula PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B39,B7801,B3901	LMX
Bengochea, Carrett	33	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+	+	+	+		+		+									B82,A23,B8,A2403 >	LMX
Cecka, J. Michael P	96	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A23,B39	LMX
Chen, Dong-Feng P		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		CW4,A203,A2,A29 >	LMX
Dunn, Paul		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A203,A2,A66 >	LMX
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A2,A23,A69,B65 >	LMX
Fort, Marylise	NT																																					LMX
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A2,A23,A68 >	LMX
Hamdi, Nuha	98	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A2,A34,A23 >	LMX
Hod, Reut	98	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+	+		+	A2,B82,B39,B8	LMX
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A2,A66,A25 >	LMX
Lardy, N.M.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				+								+		LMX
Libyh/Roulin, Tabary	96	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		CW4,A23,CW10,CW9 >	LMX
Martinho, Paiva &		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A23,B65,B39 >	LMX
McCoy, Heather	51	+	+	+	+	+	+	+	+	+	+	+						+	+					+	+		+		+		+	+		+	+		A26,A23,CW10	LMX
Pancoska, Carol Ph	59	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A2,A23,A69 >	LMX
Permpikul, Vejbaesy	42	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+		+	+	B39	LMX
Phelan, Donna L.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A23,B39,CW10 >	LMX
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A2,A66,A29 >	LMX
Rosen-Bronson, Sa		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A2,A23,A69 >	LMX
Terasaki, Paul I. Ph		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A34,A23,B39 >	LMX
Thornton, Alycia		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+	A2,B82,B7,B39 >	LMX
Vasilescu, Rodica		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A2,A34,A29 >	LMX
Vather, Kuben		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A2,A23,A69 >	LMX

Table 28. Individual laboratory results for Serum #1173 - 1176 by ELISA, C1q, and Flow Cytometry

**** Serum 1173 ****																																		
Investigator	% POS	A29	B44	B45	A2	A25	A26	A3	A30	A31	A32	A33	A34	A66	A68	A69	A74	B18	B37	B38	B39	B41	B42	B54	B55	B59	B65	B67	B7	B8	A23		Other	Method
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			Elisa
McCoy, Heather	73	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		A11,B60,B61,B48 >	Elisa
Phelan, Donna L.		+	+	+																													A43,B76,B82	C1q
Eckels/CPMC,	99																																	FC

	**** Serum 1174 ****																																	
Investigator	% POS	A1	A29	A36	A2	A26	A68	A69	A80	B13	B35	B41	B42	B49	B50	B53	B55	B56	B62	B63	B71	B72	B75	A23	B51								Other	Method
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+									Elisa
McCoy, Heather	76	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+								A24,A66,B78,B52 >	Elisa
Phelan, Donna L.		+	+	+																														C1q
Eckels/CPMC,	96																																	FC

	**** Serum 1175 ****																																	
Investigator	% POS	A23	A24	A25	A32	B38	B49	B51	B52	B53	B57	B58	B59	B63	A1	A11	A2	A29	A3	A31	A33	A68	A69	A74	A80	B13	B27	B37	B44	B45	B47	B54	Other	Method
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B48,B78,B75,B7 >	Elisa
McCoy, Heather	80	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B60,B61,A66	Elisa
Phelan, Donna L.		+	+	+	+	+	+	+	+	+	+	+	+	+																			Cw4	C1q
Eckels/CPMC,	89																																	FC

	**** Serum 1176 ****																																	
Investigator	% POS	B49	B50	B51	B53	B72	A23	B13	B18	B35	B37	B38	B41	B44	B45	B47	B48	B52	B55	B56	B57	B58	B59	B60	B61	B62	B63	B71	B75	B78			Other	Method
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				Elisa
McCoy, Heather	69	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			A11,A24,B54,A29 >	Elisa
Phelan, Donna L.		+	+	+	+	+																												C1q
Eckels/CPMC,	96																																	FC

Table 29. Individual laboratory results for Serum #1173 - 1176 by NIH, C1q, Flow Cytometry, and Other - class II

	**** Serum 1173 ****													**** Serum 1174 ****								**** Serum 1175 ****				**** Serum 1176 ****					
Investigator	% POS	DR3	DR17	DR18									Other	% POS								Other	% POS			Other	% POS				Other	Method
Claas, F.H.J.	35	+												NT									NT				NT					STD
Reed, Elaine F. PhD	47		+	+										67									91				87					EXT

	**** Serum 1173 ****													**** Serum 1174 ****								**** Serum 1175 ****				**** Serum 1176 ****					
Investigator	% POS	DQ2	DR17	DR18	DR13	DR14							Other	% POS								Other	% POS			Other	% POS				Other	Method
Phelan, Donna L.		+	+	+	+	+								NT									NT				NT					C1q
Eckels/CPMC,	99													90									75				66					FC

	**** Serum 1173 ****													**** Serum 1174 ****								**** Serum 1175 ****				**** Serum 1176 ****					
Investigator	% POS	DQ2	DR17	DR18	DR11	DR12	DR13	DR14	DR7	DR8	DR9	DQ7	Other	% POS	DR11	DR12	DR13	DR14	DR17	DR18	DR8	Other	% POS	DR10	DR4	Other	% POS	DR13	DR17	DR18	Other	Method
Phelan, Donna L.	100													91									93				43					Other
Reed, Elaine F. PhD	83	+	+	+	+	+	+	+	+	+	+	+		77	+	+	+	+	+	+	+		33	+	+		47	+	+	+		Other

STD = NIH-Standard
EXT = NIH-Extended
FC = Flow Cytometry
Other = Luminex PRA

Table 30. Individual laboratory results for Serum #1173 by Luminex - class II

	**** Serum 1173 ****																														
Investigator	% POS	DQ2	DR11	DR12	DR13	DR14	DR52	DR7	DR8	DR9	DR15	DR17	DR18	DPW4	DQ7	DPW2	DR16	DR51	DR10	DP18	DQ5	DQ6	DQ8	DQ9	DQ4	DPW1	DPW5	DP402	DPW6	DR53	Other	Method
Arnold, Paula PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+									+							LMX
Bengochea, Carrett	39	+	+	+	+	+	+	+	+	+	+						+														DR3,DR1404	LMX
Cecka, J. Michael P	94	+	+	+	+	+	+	+	+	+		+	+		+																	LMX
Chen, Dong-Feng P		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+					LMX
Dunn, Paul		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+				LMX
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					LMX
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+						LMX
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+											LMX
Hamdi, Nuha	91	+	+	+	+	+	+	+	+	+	+	+	+	+	+																	LMX
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+		+												+				LMX
Libyh/Roulin, Tabary	91	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+				LMX
Pancoska, Carol Ph	56	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				+			LMX
Permpikul, Vejbaesy	32	+	+	+	+	+	+	+	+	+	+	+	+	+																		LMX
Phelan, Donna L.		+	+	+	+	+	+	+	+	+	+	+	+		+	+									+							LMX
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+							+		LMX
Rosen-Bronson, Sar	97	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+													LMX
Thornton, Alycia		+	+	+	+	+	+	+	+	+	+	+	+				+	+															LMX
Vather, Kuben		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	DR1,DR103,DR4,DPW3 >	LMX
Vather, Nelson/		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	DPW3,DP9,DP10,DP11 >	LMX

Table 31. Individual laboratory results for Serum #1174 by Luminex - class II

	**** Serum 1174 ****																
Investigator	% POS	DR10	DR11	DR12	DR13	DR14	DR8	DR9	DR53	DR17	DR18	DR52	DR7	DQ2	DQ5	Other	Method
Arnold, Paula PhD		+	+	+	+	+	+	+	+	+	+						LMX
Bengochea, Carrett	22	+	+	+	+	+	+	+	+			+	+			DR3,DR1404	LMX
Cecka, J. Michael P	89	+	+	+	+	+	+	+	+	+	+	+					LMX
Chen, Dong-Feng P		+	+	+	+	+	+	+	+	+	+	+	+	+			LMX
Dunn, Paul		+	+	+	+	+	+	+	+	+	+	+	+	+			LMX
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+					LMX
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+	+	+			LMX
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+				LMX
Hamdi, Nuha	89	+	+	+	+	+	+	+	+	+	+	+		+			LMX
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Libyh/Roulin, Tabary	89	+	+	+	+	+	+	+	+	+	+	+					LMX
Pancoska, Carol Ph	23	+	+	+	+	+	+	+	+	+	+	+					LMX
Permpikul, Vejbaesy	18	+	+	+	+	+	+	+	+	+	+						LMX
Phelan, Donna L.		+	+	+	+	+	+	+	+	+	+						LMX
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+			LMX
Rosen-Bronson, Sa	93	+	+	+	+	+	+	+	+	+	+	+	+				LMX
Thornton, Alycia		+	+	+	+	+	+	+	+	+	+	+	+				LMX
Vather, Kuben		+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Vather, Nelson/		+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX

Table 32. Individual laboratory results for Serum #1175 - 1176 by Luminex - class II

	**** Serum 1175 ****																			**** Serum 1176 ****										
Investigator	% POS	DR4	DR10	DR53	DR9	DQ9	DQ8	DQ7	DR1	DR7	DR103	DR15	DR16	DR51	DQ2	DQ5	DR52	DQ6	Other	% POS	DR17	DR18	DR52	DR14	DR13	DQ2	DR11	DP11	Other	Method
Arnold, Paula PhD		+																			+	+								LMX
Bengochea, Carrett	12	+	+	+	+				+	+										13			+	+	+		+		DR3,DR1404	LMX
Cecka, J. Michael P	17	+	+	+	+	+	+	+												34	+	+		+	+					LMX
Chen, Dong-Feng P		+	+	+		+	+	+													+	+	+	+	+					LMX
Dunn, Paul		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+	+	+	+	+	+	+	DQ5,DPW6	LMX
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+			+						+	+	+							LMX
Fort, Marylise	NT																			NT										LMX
Hahn, Amy B. PhD		+	+	+	+								+				+		DR11,DR14,DP10,DP18		+	+	+	+	+					LMX
Hamdi, Nuha	34	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		54	+	+	+	+	+	+				LMX
Holdsworth, Rhonda	?																				+	+	+	+	+	+	+		DR12	LMX
Libyh/Roulin, Tabary	26	+	+	+	+	+	+	+	+	+	+	+	+	+					DPW4,DP11,DP15	57	+	+	+		+					LMX
Pancoska, Carol Ph	37	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				7	+	+	+	+	+					LMX
Permpikul, Vejbaesy	14	+	+	+	+	+														8	+	+								LMX
Phelan, Donna L.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					+	+								LMX
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+		+							+	+	+	+	+					LMX
Rosen-Bronson, Sar	38	+	+	+	+	+	+	+												62	+	+	+					+		LMX
Thornton, Alycia		+	+	+	+																+	+	+	+						LMX
Vather, Kuben		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+	+	+	+	+				LMX
Vather, Nelson/		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DR8,DR14,DQ4,DPW1 >		+	+	+	+	+	+	+	+	DQ5,DPW6	LMX

NEXT MAILING DATE: August 5, 2015

Arlene Locke, David Gjertson, Qiuheng Zhang, and Elaine F. Reed